Multi-event July 2013 FDA Recall Drug by Aidapak Services, Llc

This Multi-event Class II drug recall was voluntarily initiated by Aidapak Services, Llc on July 2, 2013 for the product Drug. The FDA reported the reason for recall as labeling. The product was distributed in Repacked drugs were distributed in Arizona, California, Oregon, and Washington. and the recall is currently terminated.

Reported Recall Events

D-818-2014 TERMINATED D-783-2014 TERMINATED D-867-2014 TERMINATED D-830-2014 TERMINATED D-928-2014 TERMINATED D-915-2014 TERMINATED D-865-2014 TERMINATED D-815-2014 TERMINATED D-806-2014 TERMINATED D-797-2014 TERMINATED D-926-2014 TERMINATED D-956-2014 TERMINATED D-850-2014 TERMINATED D-898-2014 TERMINATED D-885-2014 TERMINATED D-919-2014 TERMINATED D-999-2014 TERMINATED D-809-2014 TERMINATED D-975-2014 TERMINATED D-794-2014 TERMINATED D-910-2014 TERMINATED D-822-2014 TERMINATED D-786-2014 TERMINATED D-942-2014 TERMINATED D-996-2014 TERMINATED D-864-2014 TERMINATED D-1019-2014 TERMINATED D-858-2014 TERMINATED D-945-2014 TERMINATED D-971-2014 TERMINATED D-930-2014 TERMINATED D-997-2014 TERMINATED D-1026-2014 TERMINATED D-948-2014 TERMINATED D-804-2014 TERMINATED D-802-2014 TERMINATED D-868-2014 TERMINATED D-988-2014 TERMINATED D-907-2014 TERMINATED D-904-2014 TERMINATED D-920-2014 TERMINATED D-913-2014 TERMINATED D-843-2014 TERMINATED D-869-2014 TERMINATED D-899-2014 TERMINATED D-925-2014 TERMINATED D-906-2014 TERMINATED D-935-2014 TERMINATED D-914-2014 TERMINATED D-989-2014 TERMINATED D-922-2014 TERMINATED D-1013-2014 TERMINATED D-813-2014 TERMINATED D-934-2014 TERMINATED D-848-2014 TERMINATED D-808-2014 TERMINATED D-972-2014 TERMINATED D-938-2014 TERMINATED D-892-2014 TERMINATED D-879-2014 TERMINATED D-866-2014 TERMINATED D-785-2014 TERMINATED D-952-2014 TERMINATED D-998-2014 TERMINATED D-1011-2014 TERMINATED D-923-2014 TERMINATED D-993-2014 TERMINATED D-812-2014 TERMINATED D-991-2014 TERMINATED D-936-2014 TERMINATED D-782-2014 TERMINATED D-932-2014 TERMINATED D-788-2014 TERMINATED D-871-2014 TERMINATED D-1029-2014 TERMINATED D-863-2014 TERMINATED D-969-2014 TERMINATED D-839-2014 TERMINATED D-845-2014 TERMINATED D-1002-2014 TERMINATED D-984-2014 TERMINATED D-994-2014 TERMINATED D-941-2014 TERMINATED D-772-2014 TERMINATED D-1017-2014 TERMINATED D-836-2014 TERMINATED D-1014-2014 TERMINATED D-847-2014 TERMINATED D-960-2014 TERMINATED D-943-2014 TERMINATED D-826-2014 TERMINATED D-903-2014 TERMINATED D-986-2014 TERMINATED D-829-2014 TERMINATED D-1008-2014 TERMINATED D-768-2014 TERMINATED D-965-2014 TERMINATED D-835-2014 TERMINATED D-927-2014 TERMINATED D-844-2014 TERMINATED D-837-2014 TERMINATED D-790-2014 TERMINATED D-881-2014 TERMINATED D-861-2014 TERMINATED D-982-2014 TERMINATED D-908-2014 TERMINATED D-856-2014 TERMINATED D-921-2014 TERMINATED D-950-2014 TERMINATED D-834-2014 TERMINATED D-955-2014 TERMINATED D-1004-2014 TERMINATED D-792-2014 TERMINATED D-1023-2014 TERMINATED D-774-2014 TERMINATED D-924-2014 TERMINATED D-995-2014 TERMINATED D-787-2014 TERMINATED D-769-2014 TERMINATED D-909-2014 TERMINATED D-870-2014 TERMINATED D-1025-2014 TERMINATED D-849-2014 TERMINATED D-877-2014 TERMINATED D-886-2014 TERMINATED D-895-2014 TERMINATED D-817-2014 TERMINATED D-810-2014 TERMINATED D-784-2014 TERMINATED D-1010-2014 TERMINATED D-974-2014 TERMINATED D-883-2014 TERMINATED D-893-2014 TERMINATED D-951-2014 TERMINATED D-859-2014 TERMINATED D-891-2014 TERMINATED D-767-2014 TERMINATED D-773-2014 TERMINATED D-770-2014 TERMINATED D-825-2014 TERMINATED D-933-2014 TERMINATED D-954-2014 TERMINATED D-992-2014 TERMINATED D-897-2014 TERMINATED D-939-2014 TERMINATED D-872-2014 TERMINATED D-771-2014 TERMINATED D-980-2014 TERMINATED D-957-2014 TERMINATED D-793-2014 TERMINATED D-853-2014 TERMINATED D-874-2014 TERMINATED D-1028-2014 TERMINATED D-1006-2014 TERMINATED D-776-2014 TERMINATED D-820-2014 TERMINATED D-854-2014 TERMINATED D-987-2014 TERMINATED D-964-2014 TERMINATED D-842-2014 TERMINATED D-901-2014 TERMINATED D-917-2014 TERMINATED D-873-2014 TERMINATED D-902-2014 TERMINATED D-900-2014 TERMINATED D-814-2014 TERMINATED D-918-2014 TERMINATED D-875-2014 TERMINATED D-887-2014 TERMINATED D-1021-2014 TERMINATED D-766-2014 TERMINATED D-789-2014 TERMINATED D-931-2014 TERMINATED D-889-2014 TERMINATED D-811-2014 TERMINATED D-852-2014 TERMINATED D-840-2014 TERMINATED D-828-2014 TERMINATED D-985-2014 TERMINATED D-958-2014 TERMINATED D-1015-2014 TERMINATED D-911-2014 TERMINATED D-765-2014 TERMINATED D-781-2014 TERMINATED D-880-2014 TERMINATED D-947-2014 TERMINATED D-978-2014 TERMINATED D-816-2014 TERMINATED D-981-2014 TERMINATED D-805-2014 TERMINATED D-841-2014 TERMINATED D-1027-2014 TERMINATED D-967-2014 TERMINATED D-959-2014 TERMINATED D-949-2014 TERMINATED D-1005-2014 TERMINATED D-846-2014 TERMINATED D-1012-2014 TERMINATED D-1001-2014 TERMINATED D-937-2014 TERMINATED D-777-2014 TERMINATED D-1022-2014 TERMINATED D-831-2014 TERMINATED D-824-2014 TERMINATED D-821-2014 TERMINATED D-929-2014 TERMINATED D-966-2014 TERMINATED D-962-2014 TERMINATED D-888-2014 TERMINATED D-1016-2014 TERMINATED D-970-2014 TERMINATED D-890-2014 TERMINATED D-973-2014 TERMINATED D-983-2014 TERMINATED D-862-2014 TERMINATED D-857-2014 TERMINATED D-1007-2014 TERMINATED D-977-2014 TERMINATED D-979-2014 TERMINATED D-807-2014 TERMINATED D-799-2014 TERMINATED D-1018-2014 TERMINATED D-944-2014 TERMINATED D-905-2014 TERMINATED D-976-2014 TERMINATED D-838-2014 TERMINATED D-1000-2014 TERMINATED D-884-2014 TERMINATED D-1009-2014 TERMINATED D-912-2014 TERMINATED D-968-2014 TERMINATED D-800-2014 TERMINATED D-878-2014 TERMINATED D-860-2014 TERMINATED D-803-2014 TERMINATED D-961-2014 TERMINATED D-780-2014 TERMINATED D-778-2014 TERMINATED D-990-2014 TERMINATED D-1003-2014 TERMINATED D-916-2014 TERMINATED D-876-2014 TERMINATED D-779-2014 TERMINATED D-1020-2014 TERMINATED D-795-2014 TERMINATED D-882-2014 TERMINATED D-832-2014 TERMINATED D-791-2014 TERMINATED D-801-2014 TERMINATED D-953-2014 TERMINATED D-796-2014 TERMINATED D-851-2014 TERMINATED D-963-2014 TERMINATED D-819-2014 TERMINATED D-896-2014 TERMINATED D-798-2014 TERMINATED D-894-2014 TERMINATED D-940-2014 TERMINATED D-775-2014 TERMINATED D-1024-2014 TERMINATED D-855-2014 TERMINATED D-823-2014 TERMINATED D-827-2014 TERMINATED D-946-2014 TERMINATED D-833-2014 TERMINATED

Recall Number: D-818-2014

Reason for Recall
Labeling: Label Mixup: MYCOPHENOLIC ACID DR, Tablet, 180 mg may have potentially been mislabeled as the following drug: METHAZOLAMIDE, Tablet, 50 mg, NDC 00781107101, Pedigree: AD37072_11, EXP: 5/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
120 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MYCOPHENOLIC ACID DR, Tablet, 180 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078038566.

Batch or Lot Expiration Information

Lot# MYCOPHENOLIC ACID DR, Tablet, 180 mg has the following codes: Pedigree: AD37069_1, EXP: 5/13/2014.

Recall Number: D-783-2014

Reason for Recall
Labeling: Label Mixup: PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units may be potentially mislabeled as one of the following drugs: ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: W003726, EXP: 6/26/2014; LANTHANUM CARBONATE, CHEW Tablet, 500 mg, NDC 54092025290, Pedigree: W002790, EXP: 6/6/2014; CITALOPRAM, Tablet, 10 mg, NDC 57664050788, Pedigree: W002844, EXP: 6/7/2014; AT
Initiated
07-02-2013
Reported
01-29-2014
Quantity
400 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units, Rx only, Distributed by: AidaPak Service, LLC, NDC 00032121201.

Batch or Lot Expiration Information

Lot# PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units has the following codes: Pedigree: W003731, EXP: 6/26/2014; Pedigree: W002819, EXP: 6/7/2014; Pedigree: W002849; EXP: 6/7/2014; Pedigree: AD30180_4, EXP: 5/8/2014.

Recall Number: D-867-2014

Reason for Recall
Labeling: Label Mixup: DOXYCYCLINE HYCLATE, Capsule, 100 mg may have potentially been mislabeled as the following drug: RALOXIFENE HCL, Tablet, 60 mg, NDC 00002416530, Pedigree: W002644, EXP: 6/5/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DOXYCYCLINE HYCLATE, Capsule, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00143314250.

Batch or Lot Expiration Information

Lot# DOXYCYCLINE HYCLATE, Capsule, 100 mg has the following codes: Pedigree: W002645, EXP: 6/5/2014.

Recall Number: D-830-2014

Reason for Recall
Labeling: Label Mixup: clonazePAM, Tablet, 0.25 mg (1/2 of 0.5 mg) may have potentially been mislabeled as the following drug: CHOLECALCIFEROL, Capsule, 2000 units, NDC 00536379001, Pedigree: ADWA00002136, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
clonazePAM, Tablet, 0.25 mg (1/2 of 0.5 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00093083201.

Batch or Lot Expiration Information

Lot# clonazePAM, Tablet, 0.25 mg (1/2 of 0.5 mg) has the following codes: Pedigree: AD73518_1, EXP: 5/31/2014.

Recall Number: D-928-2014

Reason for Recall
Labeling: Label Mixup: ASPIRIN, Tablet, 325 mg may have potentially been mislabeled as one of the following drugs: PANCRELIPASE DR, Capsule, 0 mg, NDC 42865010302, Pedigree: W003354, EXP: 6/19/2014; acetaZOLAMIDE, Tablet, 250 mg, NDC 51672402301, Pedigree: W003524, EXP: 6/21/2014; METOPROLOL TARTRATE, Tablet, 25 mg, NDC 00378001801, Pedigree: W002535, EXP: 6/3/2014; RIVAROXABAN, Tablet, 20 mg,
Initiated
07-02-2013
Reported
01-29-2014
Quantity
900 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASPIRIN, Tablet, 325 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536330501.

Batch or Lot Expiration Information

Lot# ASPIRIN, Tablet, 325 mg has the following codes: Pedigree: W003355, EXP: 6/19/2014; Pedigree: W003525, EXP: 6/21/2014; Pedigree: W002573, EXP: 6/3/2014; Pedigree: W002624, EXP: 6/4/2014.

Recall Number: D-915-2014

Reason for Recall
Labeling: Label Mixup: NEBIVOLOL HCL, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: THYROID, Tablet, 30 mg, NDC 00456045801, Pedigree: AD73611_1, EXP: 5/30/2014; RASAGILINE MESYLATE, Tablet, 0.5 mg, NDC 68546014256, Pedigree: W002929, EXP: 6/10/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NEBIVOLOL HCL, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00456140530.

Batch or Lot Expiration Information

Lot# NEBIVOLOL HCL, Tablet, 5 mg has the following codes: Pedigree: AD73611_7, EXP: 5/30/2014; Pedigree: W002930, EXP: 6/10/2014.

Recall Number: D-865-2014

Reason for Recall
Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 25 mg may have potentially been mislabeled as the following drug: DULoxetine HCl DR, Capsule, 20 mg, NDC 00002323560, Pedigree AD54587_4, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
99 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CapsuleTOPRIL, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00143117201.

Batch or Lot Expiration Information

Lot# CapsuleTOPRIL, Tablet, 25 mg has the following codes: Pedigree: AD52778_19, EXP: 5/20/2014.

Recall Number: D-815-2014

Reason for Recall
Labeling: Label Mixup: VALSARTAN, Tablet, 80 mg may have potentially been mislabeled as one of the following drugs: TEMAZEPAM, Capsule, 7.5 mg, NDC 00378311001, Pedigree: AD49418_1, EXP: 5/17/2014; VALSARTAN, Tablet, 320 mg, NDC 00078036034, Pedigree: AD65475_7, EXP: 5/28/2014; ISOSORBIDE MONONITRATE, Tablet, 20 mg, NDC 62175010701, Pedigree: AD67989_10, EXP: 5/28/2014; CHOLECALCIFEROL, Tablet
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1440 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VALSARTAN, Tablet, 80 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078035834.

Batch or Lot Expiration Information

Lot# VALSARTAN, Tablet, 80 mg has the following codes: Pedigree: AD52372_4, EXP: 5/17/2014; Pedigree: AD65475_10, EXP: 5/28/2014; Pedigree: AD68025_1, EXP: 5/28/2014; Pedigree: AD70585_1, EXP: 5/29/2014; Pedigree: W002768, EXP: 6/10/2014; Pedigree: W003535, EXP: 6/21/2014; Pedigree: AD62995_4, EXP: 5/28/2014; Pedigree: AD73597_1, EXP: 5/31/2014; Pedigree: W002616, EXP: 6/4/2014.

Recall Number: D-806-2014

Reason for Recall
Labeling: Label Mixup: PREGABALIN, Capsule, 200 mg may have potentially been mislabeled as one of the following drugs: LOSARTAN POTASSIUM, Tablet, 50 mg, NDC 00781570192, Pedigree: AD21965_10, EXP: 5/1/2014; CYANOCOBALAMIN, Tablet, 500 mcg, NDC 00536355101, Pedigree: AD30180_25, EXP: 5/9/2014; clonazePAM, Tablet, 0.25 mg (1/2 of 0.5 mg), NDC 00093083201, Pedigree: AD73518_1, EXP: 5/31/2014; OM
Initiated
07-02-2013
Reported
01-29-2014
Quantity
540 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PREGABALIN, Capsule, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00071101768.

Batch or Lot Expiration Information

Lot# Labeling: Label Mixup: PREGABALIN, Capsule, 200 mg has the following codes: Pedigree: AD21787_1, EXP: 5/1/2014; Pedigree: AD30024_1, EXP: 5/9/2014; Pedigree: AD73518_4, EXP: 5/31/2014; Pedigree W002759, EXP: 6/6/2014; Pedigree: W003397, EXP: 6/19/2014; Pedigree: W003398, EXP: 6/19/2014.

Recall Number: D-797-2014

Reason for Recall
Labeling: Label Mixup: azaTHIOprine, Tablet, 50 mg may have potentially been mislabeled as the following drug: SELENIUM, Tablet, 50 mcg, NDC 00904316260, Pedigree: AD56939_1, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
azaTHIOprine, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054408425.

Batch or Lot Expiration Information

Lot# azaTHIOprine, Tablet, 50 mg has the following codes: Pedigree: AD56832_1, EXP: 5/21/2014.

Recall Number: D-926-2014

Reason for Recall
Labeling: Label Mixup: ACETAMINOPHEN, CHEW Tablet, 80 mg may have potentially been mislabeled as one of the following drugs: BENAZEPRIL HCL, Tablet, 40 mg, NDC 65162075410, Pedigree: AD49423_1, EXP: 5/16/2014; ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: W003101, EXP: 6/13/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 40985022921, Pedigree: AD30028_1, EXP: 5/8/2014; TACROLIMUS,
Initiated
07-02-2013
Reported
01-29-2014
Quantity
120 CHEW Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ACETAMINOPHEN, CHEW Tablet, 80 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536323307.

Batch or Lot Expiration Information

Lot# ACETAMINOPHEN, CHEW Tablet, 80 mg has the following codes: Pedigree: AD49399_1, EXP: 5/16/2014; Pedigree: W003113, EXP: 6/13/2014; Pedigree: AD30180_7, EXP: 5/8/2014; Pedigree: W003050, EXP: 6/12/2014.

Recall Number: D-956-2014

Reason for Recall
Labeling: Label Mixup: LIOTHYRONINE SODIUM, Tablet, 5 mcg may have potentially been mislabeled as one of the following drugs: LIOTHYRONINE SODIUM, Tablet, 25 mcg, NDC 00574022201, Pedigree: W003152, EXP: 4/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LIOTHYRONINE SODIUM, Tablet, 5 mcg, NDC 00574022001, Rx only, Distributed by: AidaPak Service, LLC, NDC 00574022001.

Batch or Lot Expiration Information

Lot# LIOTHYRONINE SODIUM, Tablet, 5 mcg has the following codes: Pedigree: W003153, EXP: 5/31/2014.

Recall Number: D-850-2014

Reason for Recall
Labeling: Label Mixup: glyBURIDE MICRONIZED, Tablet, 3 mg may have potentially been mislabeled as the following drug: DIGOXIN, Tablet, 0.125 mg, NDC 00115981101, Pedigree: W003154, EXP: 6/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
101 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
glyBURIDE MICRONIZED, Tablet, 3 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093803501.

Batch or Lot Expiration Information

Lot# glyBURIDE MICRONIZED, Tablet, 3 mg has the following codes: Pedigree: W003155, EXP: 6/13/2014.

Recall Number: D-898-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 112 mcg may have potentially been mislabeled as one of the following drugs: ZINC SULFATE, Capsule, 220 mg (50 mg Elem Zn), NDC 00904533260, Pedigree: AD57624_1, EXP: 5/9/2014; hydrALAZINE HCl, Tablet, 50 mg, NDC 50111032801, Pedigree: AD52778_28, EXP: 5/20/2014; CHOLECALCIFEROL, Capsule, 2000 units, NDC 00536379001, Pedigree: W003828, EXP: 6/
Initiated
07-02-2013
Reported
01-29-2014
Quantity
499 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 112 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378181101.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 112 mcg has the following codes: Pedigree: AD60211_1, EXP: 5/21/2014; Pedigree: AD52778_37, EXP: 5/20/2014; Pedigree: W003847, EXP: 6/27/2014; Pedigree: AD30197_13, EXP: 5/9/2014; Pedigree: AD49423_7, EXP: 5/16/2014.

Recall Number: D-885-2014

Reason for Recall
Labeling: Label Mixup: PROPRANOLOL HCL ER, Capsule, 60 mg may have potentially been mislabeled as the following drug: CINACALCET HCL, Tablet, 30 mg, NDC 55513007330, Pedigree: AD52778_82, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PROPRANOLOL HCL ER, Capsule, 60 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00228277811.

Batch or Lot Expiration Information

Lot# PROPRANOLOL HCL ER, Capsule, 60 mg has the following codes: Pedigree: AD54605_4, EXP: 5/20/2014.

Recall Number: D-919-2014

Reason for Recall
Labeling: Label Mixup: DIGOXIN, Tablet, 125 mcg may have potentially been mislabeled as the following drug: CHOLECALCIFEROL/ CALCIUM/ PHOSPHORUS, Tablet, 120 units/105 mg/81 mg, NDC 64980015001, Pedigree: W002581, EXP: 6/3/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DIGOXIN, Tablet, 125 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00527132401.

Batch or Lot Expiration Information

Lot# DIGOXIN, Tablet, 125 mcg has the following codes: Pedigree: AD76675_4, EXP: 6/3/2014.

Recall Number: D-999-2014

Reason for Recall
Labeling: Label Mixup: METHAZOLAMIDE, Tablet, 50 mg may have potentially been mislabeled as the following drug: BUPRENORPHINE HCL SL, Tablet, 2 mg, NDC 00054017613, Pedigree: AD39573_1, EXP: 5/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
METHAZOLAMIDE, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781107101.

Batch or Lot Expiration Information

Lot# METHAZOLAMIDE, Tablet, 50 mg has the following codes: Pedigree: AD37072_11, EXP: 5/13/2014.

Recall Number: D-809-2014

Reason for Recall
Labeling: Label Mixup: PARICALCITOL, Capsule, 1 mcg may have potentially been mislabeled as one of the following drugs: ASCORBIC ACID, Tablet, 500 mg, NDC 60258014101, Pedigree: AD23082_19, EXP: 5/6/2014; CHOLECALCIFEROL, Capsule, 2000 units, NDC 00536379001, Pedigree: W002666, EXP: 6/5/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PARICALCITOL, Capsule, 1 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00074431730.

Batch or Lot Expiration Information

Lot# PARICALCITOL, Capsule, 1 mcg has the following codes: Pedigree: AD23082_22, EXP: 5/6/2014; Pedigree: W002667, EXP: 6/5/2014.

Recall Number: D-975-2014

Reason for Recall
Labeling: Label Mixup:quiNIDine SULFATE, Tablet, 200 mg may have potentially been mislabeled as the following drug: QUINAPRIL, Tablet, 40 mg, NDC 31722027090, Pedigree: AD52778_76, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
quiNIDine SULFATE, Tablet, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591543801.

Batch or Lot Expiration Information

Lot# quiNIDine SULFATE, Tablet, 200 mg has the following codes: Pedigree: AD52778_79, EXP: 5/21/2014.

Recall Number: D-794-2014

Reason for Recall
Labeling: Label Mixup: CALCIUM ACETATE, Capsule, 667 mg may be potentially mislabeled as one of the following drugs: ZOLPIDEM TARTRATE, Tablet, 2.5 mg (1/2 of 5 mg), NDC 64679071401, Pedigree: AD28355_1, EXP: 5/8/2014; acetaZOLAMIDE, Tablet, 250 mg, NDC 51672402301, Pedigree: AD62865_1, EXP: 5/23/2014; ZINC GLUCONATE, Tablet, 50 mg, NDC 00904319160, Pedigree: W003028, EXP: 6/12/2014; PROPRANO
Initiated
07-02-2013
Reported
01-29-2014
Quantity
3600 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CALCIUM ACETATE, Capsule, 667 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00054008826.

Batch or Lot Expiration Information

Lot# CALCIUM ACETATE, Capsule, 667 mg has the following codes: Pedigree:AD30180_1, EXP: 5/8/2014; Pedigree:AD62865_4, EXP: 5/23/2014; Pedigree:W003045, EXP:6/12/2014; Pedigree: AD52412_11, EXP: 5/17/2014; Pedigree: AD54587_1, EXP: 5/21/2014; Pedigree: AD62986_1, EXP: 5/23/2014; Pedigree: AD73623_1, EXP: 5/30/2014; Pedigree: W003469, EXP: 6/20/2014; Pedigree: AD42592_1, EXP: 5/14/2014; Pedigree: AD52778_10, EXP: 5/20/2014; Pedigree: W003460, EXP: 6/20/2014; Pedigree: AD49463_1, EXP: 5/16/2014.

Recall Number: D-910-2014

Reason for Recall
Labeling: Label Mixup: FLUVASTATIN, Capsule, 20 mg may have potentially been mislabeled as the following drug: ACETAMINOPHEN/ BUTALBITAL/ CAFFEINE, Tablet, 325 mg/50 mg/40 mg, NDC 00603254421, Pedigree: W002654, EXP: 6/4/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FLUVASTATIN, Capsule, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378802077.

Batch or Lot Expiration Information

Lot# FLUVASTATIN, Capsule, 20 mg has the following codes: Pedigree: 00378802077, EXP: W002655.

Recall Number: D-822-2014

Reason for Recall
Labeling: Label Mixup: VENLAFAXINE HCL, Tablet, 25 mg may have potentially been mislabeled as one of the following drugs: sitaGLIPtin PHOSPHATE, Tablet, 50 mg, NDC 00006011231, Pedigree: W002824, EXP: 6/7/2014; LEVOTHYROXINE SODIUM, Tablet, 112 mcg, NDC 00378181101, Pedigree: W003847, EXP: 6/27/2014; LITHIUM CARBONATE ER, Tablet, 450 mg, NDC 00054002025, Pedigree: AD62796_1, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VENLAFAXINE HCL, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093019901.

Batch or Lot Expiration Information

Lot# VENLAFAXINE HCL, Tablet, 25 mg has the following codes: Pedigree: W002825, EXP: 12/31/2013; Pedigree: W003860, EXP: 6/27/2014; Pedigree: AD62796_4, EXP: 5/22/2014.

Recall Number: D-786-2014

Reason for Recall
Labeling: Label Mixup: PROGESTERONE, Capsule, 100 mg may be potentially mislabeled as the following drug: LEVOTHYROXINE SODIUM, Tablet, 12.5 mcg (1/2 of 25 mcg), NDC 00527134101, Pedigree: AD46265_40, EXP: 5/15/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
500 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PROGESTERONE, Capsule, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00032170801.

Batch or Lot Expiration Information

Lot# PROGESTERONE, Capsule, 100 mg has the following codes: Pedigree: AD46320_1, EXP: 5/15/2014.

Recall Number: D-942-2014

Reason for Recall
Labeling: Label Mixup: PYRIDOXINE HCL, Tablet, 100 mg may have potentially been mislabeled as one of the following drugs: CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00536355601, Pedigree: AD73627_29, EXP: 5/30/2014; COENZYME Q-10, Capsule, 100 mg, NDC 37205055065, Pedigree: W003871, EXP: 6/27/2014; VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 0 mg, NDC 40985022251, Pedigree: AD76686_1, EXP: 5/31/201
Initiated
07-02-2013
Reported
01-29-2014
Quantity
299 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PYRIDOXINE HCL, Tablet, 100 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536440901.

Batch or Lot Expiration Information

Lot# PYRIDOXINE HCL, Tablet, 100 mg has the following codes: Pedigree: AD73627_32, EXP: 5/30/2014; Pedigree: W003872, EXP: 6/27/2014; Pedigree: AD76686_4, EXP: 5/31/2014.

Recall Number: D-996-2014

Reason for Recall
Labeling: Label Mixup: CHOLECALCIFEROL, Tablet, 5000 units may have potentially been mislabeled as one of the following drugs: LACTOBACILLUS ACIDOPHILUS, Capsule, 0 mg, NDC 54629011101, Pedigree: AD65311_7, EXP: 5/24/2014; QUINAPRIL HCL, Tablet, 20 mg, NDC 68180055809, Pedigree: W003556, EXP: 6/24/2014; POTASSIUM ACID PHOSPHATE, Tablet, 500 mg, NDC 00486111101, Pedigree: AD52778_34, EXP: 5/20/2
Initiated
07-02-2013
Reported
01-29-2014
Quantity
604 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CHOLECALCIFEROL, Tablet, 5000 units, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00761017840.

Batch or Lot Expiration Information

Lot# CHOLECALCIFEROL, Tablet, 5000 units has the following codes: Pedigree: AD65457_10, EXP: 5/24/2014; Pedigree: W003557, EXP: 6/24/2014; Pedigree: AD56917_10, EXP: 5/21/2014.

Recall Number: D-864-2014

Reason for Recall
Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg) may have potentially been mislabeled as the following drug:, LUBIPROSTONE, Capsule, 24 mcg, NDC 64764024060, Pedigree: AD46312_1, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00143117101.

Batch or Lot Expiration Information

Lot# CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg) has the following codes: Pedigree: AD46312_4, EXP: 5/16/2014.

Recall Number: D-1019-2014

Reason for Recall
Labeling: Label Mixup: ASCORBIC ACID, Tablet, 500 mg may have potentially been mislabeled as the following drug: VENLAFAXINE HCL, Tablet, 100 mg, NDC 00093738301, Pedigree: AD42566_1, EXP: 5/14/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
598 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASCORBIC ACID, Tablet, 500 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904052372.

Batch or Lot Expiration Information

Lot# ASCORBIC ACID, Tablet, 500 mg has the following codes: Pedigree: AD42579_1, EXP: 5/14/2014.

Recall Number: D-858-2014

Reason for Recall
Labeling: Label Mixup: ACYCLOVIR, Tablet, 800 mg may have potentially been mislabeled as the following drug: PANTOPRAZOLE SODIUM DR, Tablet, 20 mg, NDC 64679043304, Pedigree: AD70690_4, EXP: 5/29/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ACYCLOVIR, Tablet, 800 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093894701.

Batch or Lot Expiration Information

Lot# ACYCLOVIR, Tablet, 800 mg has the following codes: Pedigree: AD70629_1, EXP: 5/29/2014.

Recall Number: D-945-2014

Reason for Recall
Labeling: Label Mixup: NIACIN TR, Tablet, 1000 mg may have potentially been mislabeled as the following drug: NIACIN TR, Tablet, 750 mg, NDC 00536703301, Pedigree: AD46414_56, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIACIN TR, Tablet, 1000 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00536703801.

Batch or Lot Expiration Information

Lot# NIACIN TR, Tablet, 1000 mg has the following codes: Pedigree: AD46414_50, EXP: 5/16/2014.

Recall Number: D-971-2014

Reason for Recall
Labeling: Label Mixup: PIOGLITAZONE, Tablet, 15 mg may have potentially been mislabeled as one of the following drugs: LACTASE ENZYME, Tablet, 3000 units, NDC 24385014976, Pedigree: AD21846_31, EXP: 5/1/2014; PHOSPHORUS, Tablet, 250 mg, NDC 64980010401, Pedigree: AD25452_7, EXP: 5/3/2014; ARIPiprazole, Tablet, 15 mg, NDC 59148000913, Pedigree: AD28322_1, EXP: 5/6/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PIOGLITAZONE, Tablet, 15 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591320530.

Batch or Lot Expiration Information

Lot# PIOGLITAZONE, Tablet, 15 mg has the following codes: Pedigree: AD22845_1, EXP: 4/30/2014; Pedigree: AD25452_10, EXP: 4/30/2014; Pedigree: AD28322_4, EXP: 4/30/2014.

Recall Number: D-930-2014

Reason for Recall
Labeling: Label Mixup: MULTIVITAMIN/MULTIMINERAL, CHEW Tablet, 0 mg may have potentially been mislabeled as one of the following drugs: MELATONIN, Tablet, 1 mg, NDC 74312002832, Pedigree: W003717, EXP: 6/26/2014; PYRIDOXINE HCL, Tablet, 50 mg, NDC 51645090901, Pedigree: AD46257_25, EXP: 5/15/2014; CHOLECALCIFEROL, Capsule, 2000 units, NDC 00536379001, Pedigree: AD73521_7, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
180 CHEW Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MULTIVITAMIN/MULTIMINERAL, CHEW Tablet, 0 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536344308.

Batch or Lot Expiration Information

Lot# MULTIVITAMIN/MULTIMINERAL, CHEW Tablet, 0 mg has the following codes: Pedigree: W003714, EXP: 6/26/2014; Pedigree: AD46257_10, EXP: 5/15/2014; Pedigree: AD73521_10, EXP: 5/30/2014.

Recall Number: D-997-2014

Reason for Recall
Labeling: Label Mixup: TRIFLUOPERAZINE HCL, Tablet, 1 mg may have potentially been mislabeled as the following drug: TERBUTALINE SULFATE, Tablet, 2.5 mg, NDC 00115261101, Pedigree: AD52778_88, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TRIFLUOPERAZINE HCL, Tablet, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781103001.

Batch or Lot Expiration Information

Lot# TRIFLUOPERAZINE HCL, Tablet, 1 mg has the following codes: Pedigree: AD52778_91, EXP: 5/21/2014.

Recall Number: D-1026-2014

Reason for Recall
Labeling: Label Mixup: TRI-BUFFERED ASPIRIN, Tablet, 325 mg may have potentially been mislabeled as the following drug: ISOMETHEPTENE MUCATE/ DICHLORALPHENAZONE/APAP, Capsule, 65 mg/100 mg/325 mg, NDC 44183044001, Pedigree: W003596, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TRI-BUFFERED ASPIRIN, Tablet, 325 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904201559.

Batch or Lot Expiration Information

Lot# TRI-BUFFERED ASPIRIN, Tablet, 325 mg has the following codes: Pedigree: W003581, EXP: 6/24/2014.

Recall Number: D-948-2014

Reason for Recall
Labeling: Label Mixup: MULTIVITAMIN/MULTIMINERAL W/IRON, CHEW Tablet, 0 mg may have potentially been mislabeled as the following drug: CHOLECALCIFEROL, Capsule, 2000 units, NDC 00536379001, Pedigree: W003017, EXP: 6/12/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
102 CHEW Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MULTIVITAMIN/MULTIMINERAL W/IRON, CHEW Tablet, 0 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536781601.

Batch or Lot Expiration Information

Lot# MULTIVITAMIN/MULTIMINERAL W/IRON, CHEW Tablet, 0 mg has the following codes: Pedigree: W003018, EXP: 6/12/2014.

Recall Number: D-804-2014

Reason for Recall
Labeling: Label Mixup: SILDENAFIL CITRATE, Tablet, 25 mg may have potentially been mislabeled as the following drug: PHENobarbital/ HYOSCYAMINE/ ATROPINE/ SCOPOLAMINE, Tablet, 16.2 mg/0.1037 mg/0.0194 mg/0.0065 mg, NDC 66213042510, Pedigree: W003640, EXP: 6/25/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SILDENAFIL CITRATE, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00069420030.

Batch or Lot Expiration Information

Lot# SILDENAFIL CITRATE, Tablet, 25 mg has the following codes: Pedigree: W003646, EXP: 6/25/2014.

Recall Number: D-802-2014

Reason for Recall
Labeling: Label Mixup: PHENOL, LOZENGE, 29 mg may have potentially been mislabeled as one of the following drugs: ATORVASTATIN CALCIUM, Tablet, 20 mg, NDC 00378201777, Pedigree: AD49582_10, EXP: 5/16/2014; VITAMIN B COMPLEX W/C, Tablet, 0 mg, NDC 00904026013, Pedigree: AD60240_48, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
180 Lozenges

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PHENOL, LOZENGE, 29 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00068021918.

Batch or Lot Expiration Information

Lot# PHENOL, LOZENGE, 29 mg has the following codes: Pedigree: AD49582_13, EXP: 5/16/2014; Pedigree: AD60428_4, EXP: 5/22/2014.

Recall Number: D-868-2014

Reason for Recall
Labeling: Label Mixup: REPAGLINIDE, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: VALSARTAN, Tablet, 40 mg, NDC 00078042315, Pedigree: AD52372_1, EXP: 5/17/2014; GUAIFENESIN, Tablet, 200 mg, NDC 00904515460, Pedigree: W002853, EXP: 6/7/2014; MAGNESIUM CHLORIDE, Tablet, 64 mg, NDC 68585000575, Pedigree: W003923, EXP: 6/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
500 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
REPAGLINIDE, Tablet, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00169008281.

Batch or Lot Expiration Information

Lot# REPAGLINIDE, Tablet, 1 mg has the following codes: Pedigree: AD52387_1, EXP: 5/17/2014; Pedigree: W002855, EXP: 6/7/2014; Pedigree: W003924, EXP: 6/28/2014.

Recall Number: D-988-2014

Reason for Recall
Labeling: Label Mixup: OXYBUTYNIN CHLORIDE, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: FLECAINIDE ACETATE, Tablet, 100 mg, NDC 00054001125, Pedigree: AD56847_4, EXP: 5/21/2014; SODIUM CHLORIDE, Tablet, 1 gm, NDC 00223176001, Pedigree: W003792, EXP: 6/27/2014; VARENICLINE, Tablet, 0.5 mg, NDC 00069046856, Pedigree: AD22616_1, EXP: 5/2/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
299 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
OXYBUTYNIN CHLORIDE, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603497521.

Batch or Lot Expiration Information

Lot# OXYBUTYNIN CHLORIDE, Tablet, 5 mg has the following codes: Pedigree: AD52778_61, EXP: 5/20/2014; Pedigree: W003898, EXP: 6/27/2014; Pedigree: AD22616_4, EXP: 5/2/2014.

Recall Number: D-907-2014

Reason for Recall
Labeling: Label Mixup: ALBUTEROL SULFATE ER, Tablet, 4 mg may have potentially been mislabeled as one of the following drugs: SIMVASTATIN, Tablet, 20 mg, NDC 16714068303, Pedigree: W003580, EXP: 6/24/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ALBUTEROL SULFATE ER, Tablet, 4 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378412201.

Batch or Lot Expiration Information

Lot# ALBUTEROL SULFATE ER, Tablet, 4 mg has the following codes: Pedigree: W003578, EXP: 6/24/2014.

Recall Number: D-904-2014

Reason for Recall
Labeling: Label Mixup: MYCOPHENOLATE MOFETIL, Capsule, 250 mg may have potentially been mislabeled as the following drug: PRAMIPEXOLE DI-HCL, Tablet, 0.25 mg, NDC 16714058501, Pedigree: W003761, EXP: 6/26/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MYCOPHENOLATE MOFETIL, Capsule, 250 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378225001.

Batch or Lot Expiration Information

Lot# MYCOPHENOLATE MOFETIL, Capsule, 250 mg has the following codes: Pedigree: W003763, EXP: 6/26/2014.

Recall Number: D-920-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 12.5 mcg (1/2 of 25 mcg) may have potentially been mislabeled as one of the following drugs: CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: AD30180_1, EXP: 5/8/2014; carBAMazepine ER, Capsule, 200 mg, NDC 66993040832, Pedigree: AD32764_14, EXP: 5/14/2014; CHLORTHALIDONE, Tablet, 12.5 mg (1/2 of 25 mg), NDC 00378022201, Pedigree:
Initiated
07-02-2013
Reported
01-29-2014
Quantity
600 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 12.5 mcg (1/2 of 25 mcg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00527134101.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 12.5 mcg (1/2 of 25 mcg) has the following codes: Pedigree: AD30140_40, EXP: 5/7/2014; Pedigree: AD46265_40, EXP: 5/15/2014; Pedigree: AD73525_49, EXP: 5/30/2014.

Recall Number: D-913-2014

Reason for Recall
Labeling: Label Mixup: THYROID, Tablet, 30 mg may have potentially been mislabeled as one of the following drugs: OMEPRAZOLE/SODIUM BICARBONATE, Capsule, 20 mg/1110 mg, NDC 11523726503, Pedigree: AD70655_20, EXP: 5/29/2014; NICOTINE POLACRILEX, LOZENGE, 2 mg, NDC 37205098769, Pedigree: AD73623_7, EXP: 5/30/2014; PYRIDOXINE HCL, Tablet, 50 mg, NDC 51645090901, Pedigree: W002697, EXP: 6/5/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
THYROID, Tablet, 30 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00456045801.

Batch or Lot Expiration Information

Lot# THYROID, Tablet, 30 mg has the following codes: Pedigree: AD65323_1, EXP: 5/29/2014; Pedigree: AD73611_1, EXP: 5/30/2014; Pedigree: W002847, EXP: 6/7/2014.

Recall Number: D-843-2014

Reason for Recall
Labeling: Label Mixup: amLODIPine BESYLATE, Tablet, 5 mg may have potentially been mislabeled as the following drug: CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00904421713, Pedigree: W002839, EXP: 6/7/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
amLODIPine BESYLATE, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093716798.

Batch or Lot Expiration Information

Lot# amLODIPine BESYLATE, Tablet, 5 mg has the following codes: Pedigree: W002840, EXP: 6/7/2014.

Recall Number: D-869-2014

Reason for Recall
Labeling: Label Mixup: REPAGLINIDE, Tablet, 2 mg may have potentially been mislabeled as one of the following drugs: COLCHICINE, Tablet, 0.6 mg, NDC 64764011907, Pedigree: AD46419_1, EXP: 5/16/2014; PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units, NDC 00032121207, Pedigree: AD70639_7, EXP: 5/29/2014; DARUNAVIR, Tablet, 800 mg, NDC 59676056630, Pedigree: W003929, EXP: 7/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
500 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
REPAGLINIDE, Tablet, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00169008481.

Batch or Lot Expiration Information

Lot# REPAGLINIDE, Tablet, 2 mg has the following codes: Pedigree: AD46419_4, EXP: 5/16/2014; Pedigree: AD70639_13, EXP: 5/29/2014; Pedigree: W003925, EXP: 7/1/2014.

Recall Number: D-899-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 175 mcg may have potentially been mislabeled as the following drug: PRAMIPEXOLE DI-HCL, Tablet, 1 mg, NDC 16714058701, Pedigree: W003150, EXP: 6/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 175 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378181701

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 175 mcg has the following codes: Pedigree: W003151, EXP: 6/13/2014.

Recall Number: D-925-2014

Reason for Recall
Labeling: Label Mixup:NICOTINE POLACRILEX, GUM, 2 mg may have potentially been mislabeled as one of the following drugs: FOLIC ACID, Tablet, 1 mg, NDC 65162036110, Pedigree: AD33897_22, EXP: 5/9/2014; QUEtiapine FUMARATE, Tablet, 25 mg, NDC 60505313001, Pedigree: W003099, EXP: 6/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1210 Pieces

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NICOTINE POLACRILEX, GUM, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00536302923.

Batch or Lot Expiration Information

Lot# NICOTINE POLACRILEX, GUM, 2 mg has the following codes: Pedigree: AD33897_28, EXP: 2/28/2014; Pedigree: W003100, EXP: 6/13/2014.

Recall Number: D-906-2014

Reason for Recall
Labeling: Label Mixup: CETIRIZINE HCL, Tablet, 5 mg may have potentially been mislabeled as the following drug: LITHIUM CARBONATE ER, Tablet, 300 mg, NDC 00054002125, Pedigree: AD39564_1, EXP: 5/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CETIRIZINE HCL, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378363501.

Batch or Lot Expiration Information

Lot# CETIRIZINE HCL, Tablet, 5 mg has the following codes: Pedigree: AD32757_13, EXP: 5/13/2014.

Recall Number: D-935-2014

Reason for Recall
Labeling: Label Mixup: DOCUSATE SODIUM, Capsule, 250 mg may have potentially been mislabeled as one of the following drugs: PIOGLITAZONE, Tablet, 15 mg, NDC 00591320530, Pedigree: AD25452_10, EXP: 4/30/2014; PHOSPHORUS, Tablet, 250 mg, NDC 64980010401, Pedigree: AD54498_1, EXP: 5/20/2014; LACTOBACILLUS GG, Capsule, 0, NDC 49100036374, Pedigree: AD65457_16, EXP: 5/24/2014; guaiFENesin ER, Table
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1204 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DOCUSATE SODIUM, Capsule, 250 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536375701.

Batch or Lot Expiration Information

Lot# DOCUSATE SODIUM, Capsule, 250 mg has the following codes: Pedigree: AD25452_13, EXP: 5/3/2014; Pedigree: AD54498_4, EXP: 5/20/2014; Pedigree: AD65457_19, EXP: 5/24/2014; Pedigree: W003358, EXP: 6/19/2014; Pedigree: W003558, EXP: 6/24/2014; Pedigree: AD60211_11, EXP: 5/22/2014; Pedigree: W003114, EXP: 6/13/2014; Pedigree: AD37063_4, EXP: 5/13/2014; Pedigree: AD73652_1, EXP: 5/29/2014.

Recall Number: D-914-2014

Reason for Recall
Labeling: Label Mixup: THYROID, Tablet, 60 mg may have potentially been mislabeled as the following drug: THYROID, Tablet, 30 mg, NDC 00456045801, Pedigree: W002847, EXP: 6/7/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
THYROID, Tablet, 60 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00456045901.

Batch or Lot Expiration Information

Lot# THYROID, Tablet, 60 mg has the following codes: Pedigree: W002848, EXP: 6/7/2014.

Recall Number: D-989-2014

Reason for Recall
Labeling: Label Mixup: PERPHENAZINE, Tablet, 16 mg may have potentially been mislabeled as one of the following drugs: MELATONIN, Tablet, 1 mg, NDC 47469000466, Pedigree: AD46257_19, EXP: 5/15/2014; LITHIUM CARBONATE ER, Tablet, 450 mg, NDC 00054002025, Pedigree: AD60272_25, EXP: 5/22/2014; MONTELUKAST SODIUM, CHEW Tablet, 4 mg, NDC 00006071131, Pedigree: AD76639_11, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
2400 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PERPHENAZINE, Tablet, 16 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603506321.

Batch or Lot Expiration Information

Lot# PERPHENAZINE, Tablet, 16 mg has the following codes: Pedigree: AD46265_49, EXP: 5/15/2014; Pedigree: AD60272_82, EXP: 5/22/2014; Pedigree: W002612, EXP: 6/4/2014.

Recall Number: D-922-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 112 mcg may have potentially been mislabeled as the following drug: RALTEGRAVIR, Tablet, 400 mg, NDC 00006022761, Pedigree: AD60272_19, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 112 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00527134601.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 112 mcg has the following codes: Pedigree: AD60272_22, EXP: 5/22/2014.

Recall Number: D-1013-2014

Reason for Recall
Labeling: Label Mixup: AMANTADINE HCL, Tablet, 100 mg may have potentially been mislabeled as one of the following drugs: MAGNESIUM CHLORIDE, Tablet, 64 mg, NDC 68585000575, Pedigree: AD52993_4, EXP: 5/17/2014; QUEtiapine FUMARATE, Tablet, 25 mg, NDC 65862048901, Pedigree: AD49582_22, EXP: 4/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
2400 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
AMANTADINE HCL, Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00832011100.

Batch or Lot Expiration Information

Lot# AMANTADINE HCL, Tablet, 100 mg has the following codes: Pedigree: AD54475_1, EXP: 5/20/2014; Pedigree: AD54475_4, EXP: 5/20/2014.

Recall Number: D-813-2014

Reason for Recall
Labeling: Label Mixup: RILUZOLE, Tablet, 50 mg may have potentially been mislabeled as the following drug: LACTOBACILLUS, Tablet, 0 mg, NDC 64980012950, Pedigree: AD62986_10, EXP: 5/23/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
120 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
RILUZOLE, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00075770060.

Batch or Lot Expiration Information

Lot# RILUZOLE, Tablet, 50 mg has the following codes: Pedigree: AD62992_11, EXP: 5/23/2014.

Recall Number: D-934-2014

Reason for Recall
Labeling: Label Mixup: DOCUSATE CALCIUM, Capsule, 240 mg may have potentially been mislabeled as one of the following drugs: diphenhydrAMINE HCl, Tablet, 25 mg, NDC 00904555159, Pedigree: AD33897_13, EXP: 5/9/2014; DUTASTERIDE, Capsule, 0.5 mg, NDC 00173071215, Pedigree: AD49610_1, EXP: 5/16/2014; diphenhydrAMINE HCl, Tablet, 25 mg, NDC 00904555159, Pedigree: W002775, EXP: 6/6/2014; VITAMIN B
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1109 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DOCUSATE CALCIUM, Capsule, 240 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536375501.

Batch or Lot Expiration Information

Lot# DOCUSATE CALCIUM, Capsule, 240 mg has the following codes: Pedigree: AD33897_16, EXP: 5/9/2014; Pedigree: AD49582_16, EXP: 5/16/2014; Pedigree: W002776, EXP: 6/6/2014; Pedigree: W003821, EXP: 6/27/2014.

Recall Number: D-848-2014

Reason for Recall
Labeling: Label Mixup: VENLAFAXINE HCL ER, Capsule, 150 mg may have potentially been mislabeled as one of the following drugs: SOTALOL HCL, Tablet, 80 mg, NDC 00093106101, Pedigree: AD30993_17, EXP: 5/9/2014; CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00904421713, Pedigree: W003075, EXP: 6/12/2014; LANTHANUM CARBONATE, CHEW Tablet, 500 mg, NDC 4092025290, Pedigree: W003410, EXP: 6/19/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
120 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VENLAFAXINE HCL ER, Capsule, 150 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093738656.

Batch or Lot Expiration Information

Lot# VENLAFAXINE HCL ER, Capsule, 150 mg has the following codes: Pedigree: AD30993_20, EXP: 5/9/2014; Pedigree: W003084, EXP: 6/12/2014; Pedigree: W003414, EXP: 6/19/2014.

Recall Number: D-808-2014

Reason for Recall
Labeling: Label Mixup: NIACIN ER, Tablet, 500 mg may have potentially been mislabeled as one of the following drugs: CHOLECALCIFEROL, Capsule, 50000 units, NDC 53191036201, Pedigree: AD60268_4, EXP: 5/22/2014; METAXALONE, Tablet, 800 mg, NDC 64720032110, Pedigree: W003738, EXP: 6/26/2014; CRANBERRY EXTRACT/VITAMIN C, Capsule, 450 mg/125 mg, NDC 31604014271, Pedigree: W003716, EXP: 6/26/2014; C
Initiated
07-02-2013
Reported
01-29-2014
Quantity
450 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIACIN ER, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00074307490.

Batch or Lot Expiration Information

Lot# NIACIN ER, Tablet, 500 mg has the following codes: Pedigree: AD60236_4, EXP: 5/22/2014; Pedigree: W003739, EXP: 6/26/2014; Pedigree: W003740, EXP: 6/26/2014; Pedigree: AD73637_1, EXP: 5/30/2014.

Recall Number: D-972-2014

Reason for Recall
Labeling: Label Mixup: CYCLOBENZAPRINE HCL, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: AD46257_62, EXP: 5/15/2014; ATENOLOL, Tablet, 12.5 mg (1/2 of 25 mg), NDC 63304062101, Pedigree: AD73525_1, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CYCLOBENZAPRINE HCL, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591325601.

Batch or Lot Expiration Information

Lot# CYCLOBENZAPRINE HCL, Tablet, 5 mg has the following codes: Pedigree: AD46265_4, 5/15/2014; Pedigree: AD73525_7, 5/30/2014.

Recall Number: D-938-2014

Reason for Recall
Labeling: Label Mixup: MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg may have potentially been mislabeled as one of the following drugs: sitaGLIPtin PHOSPHATE, Tablet, 50 mg, NDC 00006011231, Pedigree: AD62829_11, EXP: 5/23/2014; LORATADINE, Tablet, 10 mg, NDC 45802065078, Pedigree: W002652, EXP: 6/5/2014; LORATADINE, Tablet, 10 mg, NDC 45802065078, Pedigree: AD22865_7, EXP: 5/2/2014; MULTIVITAMIN/M
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1603 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536406001.

Batch or Lot Expiration Information

Lot# MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg has the following codes: Pedigree: AD62992_8, EXP: /23/2014; Pedigree: W002653, EXP: 6/5/2014; Pedigree: AD22865_10, EXP: 5/2/2014; Pedigree: AD22865_13, EXP: 5/2/2014.

Recall Number: D-892-2014

Reason for Recall
Labeling: Label Mixup: THIORIDAZINE HCL, Tablet, 50 mg may have potentially been mislabeled as the following drug: guanFACINE HCl, Tablet, 1 mg, NDC 00591044401, Pedigree: AD73525_13, EXP: 4/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
THIORIDAZINE HCL, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378061601.

Batch or Lot Expiration Information

Lot# THIORIDAZINE HCL, Tablet, 50 mg has the following codes: Pedigree: AD73525_28, EXP: 5/30/2014.

Recall Number: D-879-2014

Reason for Recall
Labeling: Label Mixup: LOVASTATIN, Tablet, 20 mg may have potentially been mislabeled as one of the following drugs: ASPIRIN EC DR, Tablet, 81 mg, NDC 49348098015, Pedigree: AD28349_1, EXP: 2/28/2014; FLUVASTATIN SODIUM, Capsule, 20 mg, NDC 00078017615, Pedigree: AD73597_7, EXP: 5/31/2014; DUTASTERIDE, Capsule, 0.5 mg, NDC 00173071204, Pedigree: W003247, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LOVASTATIN, Tablet, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00185007201.

Batch or Lot Expiration Information

Lot# LOVASTATIN, Tablet, 20 mg has the following codes: Pedigree: AD28369_1, EXP: 5/7/2014; Pedigree: AD73597_10, EXP: 5/31/2014; Pedigree: W003263, EXP: 6/17/2014.

Recall Number: D-866-2014

Reason for Recall
Labeling: Label Mixup: METHOCARBAMOL, Tablet, 500 mg may have potentially been mislabeled as the following drug: LOSARTAN POTASSIUM, Tablet, 25 mg, NDC 00093736498, Pedigree: AD46312_16, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
METHOCARBAMOL, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00143129001.

Batch or Lot Expiration Information

Lot# METHOCARBAMOL, Tablet, 500 mg has the following codes: Pedigree: AD46312_28, EXP: 5/16/2014.

Recall Number: D-785-2014

Reason for Recall
Labeling: Label Mixup: PANCRELIPASE DR, Capsule, 24000 /76000 /120000 USP units may be potentially mislabeled as one of the following drugs: SERTRALINE HCL, Tablet, 50 mg, NDC 16714061204, Pedigree: AD70585_7, EXP: 5/29/2014; THYROID, Tablet, 60 mg, NDC 00456045901, Pedigree: W002848, EXP: 6/7/2014; CHOLECALCIFEROL, Tablet, 2000 units, NDC 00904615760, Pedigree: W003744, EXP: 6/26/2014; amLOD
Initiated
07-02-2013
Reported
01-29-2014
Quantity
498 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PANCRELIPASE DR, Capsule, 24000 /76000 /120000 USP units, Rx only, Distributed by: AidaPak Service, LLC, NDC 00032122401.

Batch or Lot Expiration Information

Lot# PANCRELIPASE DR, Capsule, 24000 /76000 /120000 USP units has the following codes: Pedigree: AD70585_10, EXP: 5/29/2014 Pedigree: W002850, EXP: 6/7/2014; Pedigree: W003856, EXP: 6/26/2014 Pedigree: AD65457_4, EXP: 5/24/2014; Pedigree: AD70655_1, EXP: 5/28/2014.

Recall Number: D-952-2014

Reason for Recall
Labeling: Label Mixup: ESTRADIOL, Tablet, 0.5 mg may have potentially been mislabeled as the following drug: NICOTINE POLACRILEX, GUM, 2 mg, NDC 00536302923, Pedigree: AD33897_28, EXP: 2/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ESTRADIOL, Tablet, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00555089902.

Batch or Lot Expiration Information

Lot# ESTRADIOL, Tablet, 0.5 mg has the following codes: Pedigree: AD30993_11, EXP: 5/9/2014.

Recall Number: D-998-2014

Reason for Recall
Labeling: Label Mixup: PERPHENAZINE, Tablet, 16 mg may have potentially been mislabeled as one of the following drugs: LITHIUM CARBONATE ER, Tablet, 450 mg, NDC 00054002025, Pedigree: AD21790_28, EXP: 5/1/2014; LITHIUM CARBONATE ER, Tablet, 450 mg, NDC 00054002025, Pedigree: W002730, EXP: 6/6/2014; RALTEGRAVIR, Tablet, 400 mg, NDC 00006022761, Pedigree: W003680, EXP: 6/25/2014; VENLAFAXINE HCL
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PERPHENAZINE, Tablet, 16 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781104901.

Batch or Lot Expiration Information

Lot# PERPHENAZINE, Tablet, 16 mg has the following codes: Pedigree: AD21790_31, EXP: 5/1/2014; Pedigree: W002731, EXP: 6/6/2014; Pedigree: W003682, EXP: 6/25/2014; Pedigree: AD73525_22, EXP: 5/30/2014; Pedigree: W003328, EXP: 6/19/2014.

Recall Number: D-1011-2014

Reason for Recall
Labeling: Label Mixup: BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg may have potentially been mislabeled as the following drug: CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00904421713, Pedigree: AD32582_3, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781532531.

Batch or Lot Expiration Information

Lot# BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg has the following codes: Pedigree: AD32579_7, EXP: 5/9/2014.

Recall Number: D-923-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 175 mcg may have potentially been mislabeled as one of the following drugs: LEVOTHYROXINE SODIUM, Tablet, 88 mcg, NDC 00781518392, Pedigree: AD46265_34, EXP: 5/15/2014; hydrOXYzine PAMOATE, Capsule, 100 mg, NDC 00555032402, Pedigree: W003008, EXP: 6/11/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 175 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00527135001.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 175 mcg has the following codes: Pedigree: AD46265_37, EXP: 5/15/2014; Pedigree: W003009, EXP: 6/11/2014.

Recall Number: D-993-2014

Reason for Recall
Labeling: Label Mixup: PROPRANOLOL HCL, Tablet, 10 mg may have potentially been mislabeled as one of the following drugs: LORazepam, Tablet, 0.25 mg (1/2 of 0.5 mg), NDC 00591024001, Pedigree: AD60243_1, EXP: 5/22/2014; PROPRANOLOL HCL, Tablet, 10 mg, NDC 23155011001, Pedigree: W003068, EXP: 6/12/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PROPRANOLOL HCL, Tablet, 10 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603548221.

Batch or Lot Expiration Information

Lot# PROPRANOLOL HCL, Tablet, 10 mg has the following codes: Pedigree: AD60264_1, EXP: 5/22/2014; Pedigree: W003032, EXP: 6/12/2014.

Recall Number: D-812-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 112 mcg may have potentially been mislabeled as the following drug: MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg, NDC 00536406001, Pedigree: AD22865_13, EXP: 5/2/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 112 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00074929690.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 112 mcg has the following codes: Pedigree: AD22865_16, EXP: 5/2/2014.

Recall Number: D-991-2014

Reason for Recall
Labeling: Label Mixup: PHENobarbital, Tablet, 97.2 mg may have potentially been mislabeled as the following drug: PHENobarbital, Tablet, 64.8 mg, NDC 00603516721, Pedigree: AD73518_7, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PHENobarbital, Tablet, 97.2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603516821.

Batch or Lot Expiration Information

Lot# PHENobarbital, Tablet, 97.2 mg has the following codes: Pedigree: AD73518_10, EXP: 5/31/2014.

Recall Number: D-936-2014

Reason for Recall
Labeling: Label Mixup: DOCUSATE SODIUM, Capsule, 250 mg may have potentially been mislabeled as one of the following drugs: SACCHAROMYCES BOULARDII LYO, Capsule, 250 mg, NDC 00414200007, Pedigree: W003030, EXP: 6/12/2014; ISOSORBIDE MONONITRATE ER, Tablet, 30 mg, NDC 62175012837, Pedigree: AD21790_64, EXP: 5/1/2014; TRIHEXYPHENIDYL HCL, Tablet, 1 mg (1/2 of 2 mg), NDC 00591533501, Pedigree: AD7
Initiated
07-02-2013
Reported
01-29-2014
Quantity
16,044 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DOCUSATE SODIUM, Capsule, 250 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536375710.

Batch or Lot Expiration Information

Lot# DOCUSATE SODIUM, Capsule, 250 mg has the following codes: Pedigree: W003054, EXP: 6/12/2014; Pedigree: AD21846_11, EXP: 5/1/2014; Pedigree: W002512, EXP: 6/3/2014; Pedigree: AD76675_1, EXP: 6/3/2014; Pedigree: W002694, EXP: 6/5/2014; Pedigree: AD46257_16, EXP: 5/15/2014; Pedigree: AD60236_1, EXP: 5/22/2014; Pedigree: AD60578_5, EXP: 5/29/2014; Pedigree: AD73521_13, EXP: 5/30/2014; Pedigree: W003242, EXP: 6/17/2014; Pedigree: W003315, EXP: 6/18/2014.

Recall Number: D-782-2014

Reason for Recall
Labeling: Label Mixup: DRONEDARONE HCL, Tablet, 400 mg may be potentially as the following drug: METHYLERGONOVINE MALEATE, Tablet, 0.2 mg, NDC 43386014028, Pedigree: AD52778_40, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DRONEDARONE HCL, Tablet, 400 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00024414260.

Batch or Lot Expiration Information

Lot# DRONEDARONE HCL, Tablet, 400 mg has the following codes: Pedigree: AD52778_52, EXP: 5/20/2014.

Recall Number: D-932-2014

Reason for Recall
Labeling: Label Mixup:CYANOCOBALAMIN, Tablet, 500 mcg was mislabled as SEVELAMER CARBONATE, Tablet, 800 mg, NDC 58468013001, Pedigree: W002859, EXP: 6/7/2014. and may have potentially been mislabeled as one of the following drugs: VITAMIN B COMPLEX W/C, Tablet, 0, NDC 00536730001, Pedigree: AD52993_7, EXP: 5/20/2014; CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00536355601, Pedigree: AD30180_22, EXP:
Initiated
07-02-2013
Reported
01-29-2014
Quantity
700 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CYANOCOBALAMIN, Tablet, 500 mcg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536355101.

Batch or Lot Expiration Information

Lot# CYANOCOBALAMIN, Tablet, 500 mcg has the following codes: Pedigree: AD52993_19, EXP: 5/20/2014; Pedigree: AD30180_25, EXP: 5/9/2014; Pedigree: AD37056_10, EXP: 5/10/2014; Pedigree: AD60578_16, EXP: 5/29/2014; Pedigree: W002860, EXP: 6/7/2014.

Recall Number: D-788-2014

Reason for Recall
Labeling: Label Mixup: FLECAINIDE ACETATE, Tablet, 100 mg may be potentially mislabeled as the following drug: COLESTIPOL HCL MICRONIZED, Tablet, 1 g, NDC 59762045001, Pedigree: AD56847_1, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FLECAINIDE ACETATE, Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054001125.

Batch or Lot Expiration Information

Lot# FLECAINIDE ACETATE, Tablet, 100 mg has the following codes: Pedigree: AD56847_4, EXP: 5/21/2014.

Recall Number: D-871-2014

Reason for Recall
Labeling: Label Mixup: FLUCONAZOLE, Tablet, 200 mg may have potentially been mislabeled as one of the following drugs: VALSARTAN, Tablet, 80 mg, NDC 00078035834, Pedigree: AD65475_10, EXP: 5/28/2014; FLUCONAZOLE, Tablet, 100 mg, NDC 68462010230, Pedigree: W003064, EXP: 6/12/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FLUCONAZOLE, Tablet, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00172541360.

Batch or Lot Expiration Information

Lot# FLUCONAZOLE, Tablet, 200 mg has the following codes: Pedigree: AD65475_16, EXP: 5/28/2014; Pedigree: W003065, EXP: 6/12/2014.

Recall Number: D-1029-2014

Reason for Recall
Labeling: Label Mixup :SELENIUM, Tablet, 50 mcg may have potentially been mislabeled as the following drug: guaiFENesin ER, Tablet, 600 mg, NDC 63824000815, Pedigree: AD56917_13, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SELENIUM, Tablet, 50 mcg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904316260.

Batch or Lot Expiration Information

Lot# SELENIUM, Tablet, 50 mcg has the following codes: Pedigree: AD56939_1, EXP: 5/21/2014.

Recall Number: D-863-2014

Reason for Recall
Labeling: Label Mixup: CapsuleTOPRIL, Tablet, 12.5 mg may have potentially been mislabeled as the following drug:, CALCITRIOL, Capsule, 0.25 mcg, NDC 00054000725, Pedigree: AD52778_13, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CapsuleTOPRIL, Tablet, 12.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00143117101.

Batch or Lot Expiration Information

Lot# CapsuleTOPRIL, Tablet, 12.5 mg has the following codes: Pedigree: AD52778_16, EXP: 5/20/2014.

Recall Number: D-969-2014

Reason for Recall
Labeling: Label Mixup: CLINDAMYCIN HCL, Capsule, 300 mg may have potentially been mislabeled as the following drug: MELATONIN, Tablet, 3 mg, NDC 51991001406, Pedigree: AD68019_7, EXP: 5/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CLINDAMYCIN HCL, Capsule, 300 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591312001.

Batch or Lot Expiration Information

Lot# CLINDAMYCIN HCL, Capsule, 300 mg has the following codes: Pedigree: AD67989_1, EXP: 5/28/2014.

Recall Number: D-839-2014

Reason for Recall
Labeling: Label Mixup: ESCITALOPRAM, Tablet, 5 mgmay have potentially been mislabeled as the following drug: SODIUM CHLORIDE, Tablet, 1 gm, NDC 00223176001, Pedigree: W003707, EXP: 6/25/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ESCITALOPRAM, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093585001.

Batch or Lot Expiration Information

Lot# ESCITALOPRAM, Tablet, 5 mg has the following codes: Pedigree: W003733, EXP: 6/26/2014.

Recall Number: D-845-2014

Reason for Recall
Labeling: Label Mixup: LOSARTAN POTASSIUM, Tablet, 50 mg may have potentially been mislabeled as the following drug: MIDODRINE HCL, Tablet, 2.5 mg, NDC 00185004001, Pedigree: W003265, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LOSARTAN POTASSIUM, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093736598.

Batch or Lot Expiration Information

Lot# LOSARTAN POTASSIUM, Tablet, 50 mg has the following codes: Pedigree: W003268, EXP: 6/17/2014.

Recall Number: D-1002-2014

Reason for Recall
Labeling: Label Mixup: IMIPRAMINE HCL, Tablet, 25 mg may have potentially been mislabeled as the following drug: FENOFIBRATE, Tablet, 54 mg, NDC 00115551110, Pedigree: AD49448_7, EXP: 5/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
IMIPRAMINE HCL, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781176401.

Batch or Lot Expiration Information

Lot# IMIPRAMINE HCL, Tablet, 25 mg has the following codes: Pedigree: AD49448_10, EXP: 5/17/2014.

Recall Number: D-984-2014

Reason for Recall
Labeling: Label Mixup: HYDROCORTISONE, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: carBAMazepine ER, Tablet, 200 mg, NDC 51672412401, Pedigree: AD60272_7, EXP: 5/22/2014; guanFACINE HCl, Tablet, 1 mg, NDC 00591044401, Pedigree: W002728, EXP: 4/30/2014; glyBURIDE, Tablet, 1.25 mg, NDC 00093834201, Pedigree: AD21790_10, EXP: 2/28/2014; ACARBOSE, Tablet, 25 mg
Initiated
07-02-2013
Reported
01-29-2014
Quantity
250 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
HYDROCORTISONE, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603389919.

Batch or Lot Expiration Information

Lot# HYDROCORTISONE, Tablet, 5 mg has the following codes: Pedigree: AD60272_13, EXP: 5/22/2014; Pedigree: W002729, EXP: 6/6/2014; Pedigree: AD21790_16, EXP: 5/1/2014; Pedigree: W003060, EXP: 6/12/2014; Pedigree: W003325, EXP: 6/18/2014.

Recall Number: D-994-2014

Reason for Recall
Labeling: Label Mixup: sulfaSALAzine, Tablet, 500 mg may have potentially been mislabeled as one of the following drugs: FLUCONAZOLE, Tablet, 200 mg, NDC 00172541360, Pedigree: AD65475_16, EXP: 5/28/2014; PHENYTOIN SODIUM ER, Capsule, 30 mg, NDC 00071374066, Pedigree: W003331, EXP: 6/19/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
299 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
sulfaSALAzine, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603580121.

Batch or Lot Expiration Information

Lot# has the following codes: Pedigree: AD65475_19, EXP: 5/28/2014; Pedigree: W003335, EXP: 6/19/2014.

Recall Number: D-941-2014

Reason for Recall
Labeling: Label Mixup: PYRIDOXINE HCL, Tablet, 50 mg may have potentially been mislabeled as one of the following drugs: LACTOBACILLUS GG, Capsule, 15 Billion Cells, NDC 49100036374, Pedigree: W003787, EXP: 6/27/2014; LEVOTHYROXINE/ LIOTHYRONINE, Tablet, 19 mcg/4.5 mcg, NDC 42192032901, Pedigree: AD30197_19, EXP: 3/31/2014; CALCIUM/ CHOLECALCIFEROL/ SODIUM, Tablet, 600 mg/400 units/5 mg, NDC 00
Initiated
07-02-2013
Reported
01-29-2014
Quantity
695 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PYRIDOXINE HCL, Tablet, 50 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536440801.

Batch or Lot Expiration Information

Lot# PYRIDOXINE HCL, Tablet, 50 mg has the following codes: Pedigree: W003824, EXP: 6/27/2014; Pedigree: AD30197_22, EXP: 5/9/2014; Pedigree: AD60428_10, EXP: 5/22/2014.

Recall Number: D-772-2014

Reason for Recall
Labeling: Label Mixup: MYCOPHENOLATE MOFETIL, Tablet, 500 mg may be potentially mis-labeled as the following drug: MYCOPHENOLATE MOFETIL, Capsule, 250 mg, NDC 00004025901, Pedigree: AD49414_1, EXP: 5/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MYCOPHENOLATE MOFETIL, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00004026001.

Batch or Lot Expiration Information

Lot# MYCOPHENOLATE MOFETIL, Tablet, 500 mg has the following codes: Pedigree: AD49414_4, EXP: 5/17/2014.

Recall Number: D-1017-2014

Reason for Recall
Labeling: Label Mixup: PYRIDOXINE HCL, Tablet, 50 mg may have potentially been mislabeled as one of the following drugs: MELATONIN, Tablet, 1 mg, NDC 04746900466, Pedigree: AD21846_17, EXP: 5/1/2014; METHOCARBAMOL, Tablet, 500 mg, NDC 00143129001, Pedigree: AD46312_28, EXP: 5/16/2014; LEVOTHYROXINE SODIUM, Tablet, 112 mcg, NDC 00074929690, Pedigree: AD22865_16, EXP: 5/2/2014; RILUZOLE, Tablet,
Initiated
07-02-2013
Reported
01-29-2014
Quantity
403 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PYRIDOXINE HCL, Tablet, 50 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904052060.

Batch or Lot Expiration Information

Lot# PYRIDOXINE HCL, Tablet, 50 mg has the following codes: Pedigree: AD22865_19, EXP: 5/2/2014; Pedigree: AD46312_34, EXP: 5/16/2014; Pedigree: AD22865_22, EXP: 5/2/2014; Pedigree: W003257, EXP: 6/17/2014.

Recall Number: D-836-2014

Reason for Recall
Labeling: Label Mixup: DISOPYRAMIDE PHOSPHATE, Capsule, 150 mg may have potentially been mislabeled as the following drug: THYROID, Tablet, 30 mg, NDC 00456045801, Pedigree: AD65323_1, EXP: 5/29/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DISOPYRAMIDE PHOSPHATE, Capsule, 150 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093312901.

Batch or Lot Expiration Information

Lot# DISOPYRAMIDE PHOSPHATE, Capsule, 150 mg has the following codes: Pedigree: AD65323_4, EXP: 5/29/2014.

Recall Number: D-1014-2014

Reason for Recall
Labeling: Label Mixup: chlorproMAZINE HCl, Tablet, 50 mg may have potentially been mislabeled as the following drug: ACAMPROSATE CALCIUM DR, Tablet, 333 mg, NDC 00456333001, Pedigree: AD32973_1, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
chlorproMAZINE HCl, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00832030200.

Batch or Lot Expiration Information

Lot# chlorproMAZINE HCl, Tablet, 50 mg has the following codes: Pedigree: AD32973_4, EXP: 5/9/2014.

Recall Number: D-847-2014

Reason for Recall
Labeling: Label Mixup: VENLAFAXINE HCL, Tablet, 100 mg may have potentially was mislabeled as tiZANidine HCl, Tablet, 2 mg, NDC 55111017915, Pedigree: AD73525_31, EXP: 5/30/2014; and may have potentially been mislabeled as one of the following drugs: methylPREDNISolone, Tablet, 4 mg, NDC 00603459321, Pedigree: AD32764_11, EXP: 3/31/2014; PROPRANOLOL HCL, Tablet, 10 mg, NDC 23155011001, Pedigree:
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VENLAFAXINE HCL, Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093738301.

Batch or Lot Expiration Information

Lot# VENLAFAXINE HCL, Tablet, 100 mg has the following codes: Pedigree: AD73525_37, EXP: 5/30/2014; Pedigree: AD42566_1, EXP: 5/14/2014; Pedigree: W002619, EXP: 6/4/2014.

Recall Number: D-960-2014

Reason for Recall
Labeling: Label Mixup: LORazepam, Tablet, 0.25 mg (1/2 of 0.5 mg) may have potentially been mislabeled as the following drug: traMADol HCl, Tablet, 25 mg (1/2 of 50 mg), NDC 57664037708, Pedigree: AD60272_92, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LORazepam, Tablet, 0.25 mg (1/2 of 0.5 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00591024001.

Batch or Lot Expiration Information

Lot# LORazepam, Tablet, 0.25 mg (1/2 of 0.5 mg) has the following codes: Pedigree: AD60243_1, EXP: 5/22/2014.

Recall Number: D-943-2014

Reason for Recall
Labeling: Label Mixup: VITAMIN B COMPLEX, Capsule, 0 mg may have potentially been mislabeled as the following drug: ACARBOSE, Tablet, 25 mg, NDC 23155014701, Pedigree: AD32757_1, EXP: 5/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
399 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VITAMIN B COMPLEX, Capsule, 0 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536478701.

Batch or Lot Expiration Information

Lot# VITAMIN B COMPLEX, Capsule, 0 mg has the following codes: Pedigree: AD32757_4, EXP: 5/13/2014.

Recall Number: D-826-2014

Reason for Recall
Labeling: Label Mixup: PIROXICAM, Capsule, 10 mg may have potentially been mislabeled as the following drug: HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, NDC 00574025001, Pedigree: AD30140_10, EXP: 5/7/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PIROXICAM, Capsule, 10 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093075601.

Batch or Lot Expiration Information

Lot# PIROXICAM, Capsule, 10 mg has the following codes: Pedigree: AD21836_1, EXP: 3/31/2014.

Recall Number: D-903-2014

Reason for Recall
Labeling: Label Mixup: ATORVASTATIN CALCIUM, Tablet, 80 mg may have potentially been mislabeled as one of the following drugs: OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 11845014882, Pedigree: AD70700_7, EXP: 5/29/2014; TACROLIMUS, Capsule, 0.5 mg, NDC 00781210201, Pedigree: W003169, EXP: 6/13/2014; LEVOTHYROXINE SODIUM, Tablet, 88 mcg, NDC 00378180701, Pedigree: AD42584_1, EXP: 5/14/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
270 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATORVASTATIN CALCIUM, Tablet, 80 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378212277.

Batch or Lot Expiration Information

Lot# ATORVASTATIN CALCIUM, Tablet, 80 mg has the following codes: Pedigree: AD73627_1, EXP: 5/30/2014; Pedigree: W003213, EXP: 6/14/2014; Pedigree: AD46300_1, EXP: 5/15/2014.

Recall Number: D-986-2014

Reason for Recall
Labeling: Label Mixup: MODAFINIL, Tablet, 200 mg may have potentially been mislabeled as one of the following drugs: OMEGA-3-ACID ETHYL ESTERS, Capsule, 1000 mg, NDC 00173078302, Pedigree: W003692, EXP: 6/26/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MODAFINIL, Tablet, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603466216.

Batch or Lot Expiration Information

Lot# MODAFINIL, Tablet, 200 mg has the following codes: Pedigree: W002760, EXP: 6/6/2014; Pedigree: W003779, EXP: 6/26/2014.

Recall Number: D-829-2014

Reason for Recall
Labeling: Label Mixup: NORTRIPTYLINE HCL, Capsule, 75 mg may have potentially been mislabeled as one of the following drugs: guaiFENesin ER, Tablet, 600 mg, NDC 45802049878, Pedigree: AD21790_58, EXP: 5/1/2014; MIRTAZAPINE, Tablet, 7.5 mg, NDC 59762141509, Pedigree: W003693, EXP: 4/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NORTRIPTYLINE HCL, Capsule, 75 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093081301.

Batch or Lot Expiration Information

Lot# NORTRIPTYLINE HCL, Capsule, 75 mg has the following codes: Pedigree: AD21790_73, EXP: 5/1/2014; Pedigree: W003694, EXP: 6/26/2014.

Recall Number: D-1008-2014

Reason for Recall
Labeling: Label Mixup: methylPREDNISolone, Tablet, 4 mg may have potentially been mislabeled as one of the following drugs: LEVOTHYROXINE SODIUM, Tablet, 112 mcg, NDC 00378181101, Pedigree: AD52778_37, EXP: 5/20/2014; NABUMETONE, Tablet, 500 mg, NDC 00185014501, Pedigree: AD46426_4, EXP: 5/15/2014; CHOLECALCIFEROL, Tablet, 2000 units, NDC 00904615760, Pedigree: AD54586_10, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
methylPREDNISolone, Tablet, 4 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781502201.

Batch or Lot Expiration Information

Lot# methylPREDNISolone, Tablet, 4 mg has the following codes: Pedigree: AD52778_43, EXP: 5/20/2014; Pedigree: AD46426_10, EXP: 5/15/2014; Pedigree: AD54587_7, EXP: 5/21/2014.

Recall Number: D-768-2014

Reason for Recall
Labeling: Label Mixup: ATOMOXETINE HCL, Capsule, 80 mg may be potentially mis-labeled as one of the following drugs: ATOMOXETINE HCL, Capsule, 18 mg, NDC 00002323830, Pedigree: AD30140_16, EXP: 5/7/2014; PRENATAL MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg, NDC 00904531360, Pedigree: W003706, EXP: 6/25/2014; RANOLAZINE ER, Tablet, 500 mg, NDC 61958100301, Pedigree: AD60272_40, EXP: 5/22/2014; PRO
Initiated
07-02-2013
Reported
01-29-2014
Quantity
120 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATOMOXETINE HCL, Capsule, 80 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00002325030.

Batch or Lot Expiration Information

Lot# ATOMOXETINE HCL, Capsule, 80 mg has the following codes: Pedigree: AD30140_19, EXP: 5/7/2014; Pedigree: W003685, EXP: 6/25/2014; Pedigree: AD60272_49, EXP: 5/22/2014; Pedigree: W003003, EXP: 6/11/2014.

Recall Number: D-965-2014

Reason for Recall
Labeling: Label Mixup: guanFACINE HCl, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: buPROPion HCl ER, Tablet, 200 mg, NDC 47335073886, Pedigree: W002727, EXP: 6/6/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 00904404360, Pedigree: AD39588_7, EXP: 5/13/2014; OMEPRAZOLE/SODIUM BICARBONATE, Capsule, 20 mg/1,100 mg, NDC 11523726503, Pedigree: W003873, EXP: 6/2
Initiated
07-02-2013
Reported
01-29-2014
Quantity
500 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
guanFACINE HCl, Tablet, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591044401.

Batch or Lot Expiration Information

Lot# guanFACINE HCl, Tablet, 1 mg has the following codes: Pedigree: W002728, EXP: 4/30/2014; Pedigree: AD39611_1, EXP: 4/30/2014; Pedigree: W003791, EXP: 6/27/2014; Pedigree: AD73525_13, EXP: 4/30/2014.

Recall Number: D-835-2014

Reason for Recall
Labeling: Label Mixup: PIOGLITAZONE HCL, Tablet, 15 mg may have potentially been mislabeled as one of the following drugs: DOXYCYCLINE MONOHYDRATE, Capsule, 100 mg, NDC 49884072703, Pedigree: AD52778_25, EXP: 5/20/2014; LOVASTATIN, Tablet, 20 mg, NDC 00185007201, Pedigree: W003263, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PIOGLITAZONE HCL, Tablet, 15 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093204856.

Batch or Lot Expiration Information

Lot# PIOGLITAZONE HCL, Tablet, 15 mg has the following codes: Pedigree: AD52778_70, EXP: 5/21/2014; Pedigree: W003264, EXP: 6/17/2014.

Recall Number: D-927-2014

Reason for Recall
Labeling: Label Mixup: ASPIRIN, CHEW Tablet, 81 mg may have potentially been mislabeled as one of the following drugs: OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 40985022921, Pedigree: AD30028_4, EXP: 5/8/2014; MODAFINIL, Tablet, 200 mg, NDC 00603466216, Pedigree: W002760, EXP: 6/6/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 40985022921, Pedigree: W003015, EXP: 6/12/2014; VITAMIN B COMPLEX
Initiated
07-02-2013
Reported
01-29-2014
Quantity
4246 CHEW Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASPIRIN, CHEW Tablet, 81 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536329736.

Batch or Lot Expiration Information

Lot# ASPIRIN, CHEW Tablet, 81 mg has the following codes: Pedigree: AD33897_1, EXP: 5/9/2014; Pedigree: W002773, EXP: 6/6/2014; Pedigree: W003093, EXP: 6/13/2014; Pedigree: W003459, EXP: 6/20/2014; Pedigree: AD49582_1, EXP: 5/16/2014.

Recall Number: D-844-2014

Reason for Recall
Labeling: Label Mixup: LOSARTAN POTASSIUM, Tablet, 25 mg may have potentially been mislabeled as the following drug: PHYTONADIONE, Tablet, 5 mg, NDC 25010040515, Pedigree: AD46312_22, EXP: 4/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LOSARTAN POTASSIUM, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093736498.

Batch or Lot Expiration Information

Lot# LOSARTAN POTASSIUM, Tablet, 25 mg has the following codes: Pedigree: AD46312_16, EXP: 5/16/2014.

Recall Number: D-837-2014

Reason for Recall
Labeling: Label Mixup: BUMETANIDE, Tablet, 0.5 mg, Rx only may have potentially been mislabeled as the following drug: ERYTHROMYCIN DR EC, Tablet, 250 mg, NDC 24338012213, Pedigree: AD46426_13, EXP: 5/15/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
BUMETANIDE, Tablet, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093423201.

Batch or Lot Expiration Information

Lot# BUMETANIDE, Tablet, 0.5 mg, Rx only has the following codes: Pedigree: AD46426_25, EXP: 5/15/2014.

Recall Number: D-790-2014

Reason for Recall
Labeling: Label Mixup: LITHIUM CARBONATE ER, Tablet, 450 mg may be potentially mislabled as one of the following drugs: HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, NDC 00574025001, Pedigree: AD21790_19, EXP: 5/1/2014; LACTOBACILLUS ACIDOPHILUS, Capsule, 500 MILLION CFU, NDC 43292050022, Pedigree: AD46257_28, EXP: 5/15/2014; HYDROCORTISONE, Tablet, 5 mg, NDC 00603389919, Pedigree: W002729, EXP: 6
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1899 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LITHIUM CARBONATE ER, Tablet, 450 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054002025.

Batch or Lot Expiration Information

Lot# LITHIUM CARBONATE ER, Tablet, 450 mg has the following codes: Pedigree: AD21790_28, EXP: 5/1/2014 Pedigree: AD46265_10, EXP: 5/15/2014 Pedigree: W002730, EXP: 6/6/2014 Pedigree: W003681, EXP: 6/25/2014 Pedigree: AD60272_25, EXP: 5/22/2014 Pedigree: AD62796_1, EXP: 5/22/2014 Pedigree: W003327, EXP: 6/19/2014.

Recall Number: D-881-2014

Reason for Recall
Labeling: Label Mixup: CILOSTAZOL, Tablet, 100 mg may have potentially been mislabeled as the following drug: TRIAMTERENE/ HYDROCHLOROTHIAZIDE, Tablet, 37.5 mg/25 mg, NDC 00591042401, Pedigree: W002900, EXP: 6/10/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
63 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CILOSTAZOL, Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00185022360.

Batch or Lot Expiration Information

Lot# CILOSTAZOL, Tablet, 100 mg has the following codes: Pedigree: W002931, EXP: 6/10/2014.

Recall Number: D-861-2014

Reason for Recall
Labeling: Label Mixup: DIGOXIN, Tablet, 0.125 mg may have potentially been mislabeled as one of the following drugs: MELATONIN, Tablet, 3 mg, NDC 08770140813, Pedigree: AD21846_34, EXP: 5/1/2014; DESMOPRESSIN ACETATE, Tablet, 0.1 mg, NDC 00591246401, Pedigree: AD46426_16, EXP: 5/15/2014; PROPRANOLOL HCL, Tablet, 10 mg, NDC 00603548221, Pedigree: AD60264_1, EXP: 5/22/2014; LIOTHYRONINE SODIUM,
Initiated
07-02-2013
Reported
01-29-2014
Quantity
400 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DIGOXIN, Tablet, 0.125 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00115981101.

Batch or Lot Expiration Information

Lot# DIGOXIN, Tablet, 0.125 mg has the following codes: Pedigree: AD22609_4, EXP: 4/30/2014; Pedigree: AD46426_22, EXP: 5/15/2014; Pedigree: AD62829_8, EXP: 5/23/2014; Pedigree: W003154, EXP: 6/13/2014.

Recall Number: D-982-2014

Reason for Recall
Labeling: Label Mixup: ACETAMINOPHEN/ BUTALBITAL/ CAFFEINE, Tablet, 325 mg/50 mg/40 mg may have potentially been mislabeled as the following drug: ASPIRIN, Tablet, 325 mg, NDC 49348000123, Pedigree: W002640, EXP: 6/4/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ACETAMINOPHEN/ BUTALBITAL/ CAFFEINE, Tablet, 325 mg/50 mg/40 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603254421.

Batch or Lot Expiration Information

Lot# ACETAMINOPHEN/ BUTALBITAL/ CAFFEINE, Tablet, 325 mg/50 mg/40 mg has the following codes: Pedigree: W002654, EXP: 6/4/2014.

Recall Number: D-908-2014

Reason for Recall
Labeling: Label Mixup: VERAPAMIL HCL ER, Capsule, 240 mg may have potentially been mislabeled as the following drug: FEBUXOSTAT, Tablet, 40 mg, NDC 64764091830, Pedigree: W002664, EXP: 6/5/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VERAPAMIL HCL ER, Capsule, 240 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378644001.

Batch or Lot Expiration Information

Lot# VERAPAMIL HCL ER, Capsule, 240 mg has the following codes: Pedigree: W002665, EXP: 6/5/2014.

Recall Number: D-856-2014

Reason for Recall
Labeling: Label Mixup: MEXILETINE HCL, Capsule, 200 mg may have potentially been mislabeled as the following drug: ISOSORBIDE DINITRATE, Tablet, 10 mg, NDC 00781155601, Pedigree: AD25264_1, EXP: 5/3/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MEXILETINE HCL, Capsule, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093874001.

Batch or Lot Expiration Information

Lot# MEXILETINE HCL, Capsule, 200 mg has the following codes: Pedigree: AD25264_7, EXP: 5/3/2014.

Recall Number: D-921-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 88 mcg may have potentially been mislabeled as the following drug: guanFACINE HCl, Tablet, 1 mg, NDC 00378116001, Pedigree: W003007, EXP: 6/12/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 88 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00527134401.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 88 mcg has the following codes: Pedigree: W003010, EXP: 6/12/2014.

Recall Number: D-950-2014

Reason for Recall
Labeling: Label Mixup: chlordiazePOXIDE HCl, Capsule, 25 mg may have potentially been mislabeled as one of the following drugs: FLECAINIDE ACETATE, Tablet, 50 mg, NDC 65162064110, Pedigree: AD46414_16, EXP: 5/16/2014; CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: AD49463_1, EXP: 5/16/2014; LACTOBACILLUS GG, Capsule, 0 mg, NDC 49100036374, Pedigree: W003173, EXP: 6/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1,101 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
chlordiazePOXIDE HCl, Capsule, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00555015902.

Batch or Lot Expiration Information

Lot# chlordiazePOXIDE HCl, Capsule, 25 mg has the following codes: Pedigree: AD46333_4, EXP: 5/16/2014; Pedigree: AD49426_1, EXP: 5/16/2014; Pedigree: W003194, EXP: 6/13/2014.

Recall Number: D-834-2014

Reason for Recall
Labeling: Label Mixup: SOTALOL HCL, Tablet, 160 mg may have potentially been mislabeled as the following drug: DISULFIRAM, Tablet, 250 mg, NDC 64980017101, Pedigree: AD22609_1, EXP: 5/2/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
101 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SOTALOL HCL, Tablet, 160 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093106201.

Batch or Lot Expiration Information

Lot# SOTALOL HCL, Tablet, 160 mg has the following codes: Pedigree: AD22609_10, EXP: 4/30/2014.

Recall Number: D-955-2014

Reason for Recall
Labeling: Label Mixup: CALCIUM ACETATE, Tablet, 667 mg may have potentially been mislabeled as one of the following drugs: ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: AD30028_34, EXP: 5/7/2014; HYOSCYAMINE SULFATE ODT, Tablet, 0.125 mg, NDC 00574024701, Pedigree: W003614, EXP: 6/25/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
401 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CALCIUM ACETATE, Tablet, 667 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00574011302.

Batch or Lot Expiration Information

Lot# CALCIUM ACETATE, Tablet, 667 mg has the following codes: Pedigree: AD23098_1, EXP: 5/8/2014; Pedigree: W003637, EXP: 6/25/2014.

Recall Number: D-1004-2014

Reason for Recall
Labeling: Label Mixup: TERAZOSIN HCL, Capsule, 5 mg may have potentially been mislabeled as the following drug: DOXAZOSIN MESYLATE, Tablet, 1 mg, NDC 00093812001, Pedigree: W003912, EXP: 6/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TERAZOSIN HCL, Capsule, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781205301.

Batch or Lot Expiration Information

Lot# TERAZOSIN HCL, Capsule, 5 mg has the following codes: Pedigree: W003913, EXP: 6/28/2014.

Recall Number: D-792-2014

Reason for Recall
Labeling: Label Mixup: CILOSTAZOL, Tablet, 100 mg may be potentially mislabeled as the following drug: CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: W003469, EXP: 6/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CILOSTAZOL, Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054004421.

Batch or Lot Expiration Information

Lot# CILOSTAZOL, Tablet, 100 mg has the following codes: Pedigree: W003470, EXP: 6/20/2014.

Recall Number: D-1023-2014

Reason for Recall
Labeling: Label Mixup: NIACIN TR, Capsule, 250 mg may have potentially been mislabeled as the following drug: METHYLERGONOVINE MALEATE, Tablet, 0.2 mg, NDC 43386014028, Pedigree: W003477, EXP: 6/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIACIN TR, Capsule, 250 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00904062960.

Batch or Lot Expiration Information

Lot# NIACIN TR, Capsule, 250 mg has the following codes: Pedigree: W003478, EXP: 6/20/2014.

Recall Number: D-774-2014

Reason for Recall
Labeling: Label Mixup: sitaGLIPtin PHOSPHATE, Tablet, 50 mg may be potentially mis-labeled as one of the following drugs: LACTOBACILLUS, Tablet, 0 mg, NDC 64980012950, Pedigree: AD62992_1, EXP: 5/23/2014; CYANOCOBALAMIN, Tablet, 500 mcg, NDC 00536355101, Pedigree: W002860, EXP: 6/7/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
sitaGLIPtin PHOSPHATE, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00006011231.

Batch or Lot Expiration Information

Lot# sitaGLIPtin PHOSPHATE, Tablet, 50 mg has the following codes: Pedigree: AD62829_11, EXP: 5/23/2014; Pedigree: W002824, EXP: 6/7/2014.

Recall Number: D-924-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 137 mcg may have potentially been mislabeled as the following drug: ISONIAZID, Tablet, 300 mg, NDC 00555007102, Pedigree: AD60272_70, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 137 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00527163801.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 137 mcg has the following codes: Pedigree: AD60272_76, EXP: 5/22/2014.

Recall Number: D-995-2014

Reason for Recall
Labeling: Label Mixup: PERPHENAZINE, Tablet, 8 mg may have potentially been mislabeled as the following drug: NIFEdipine, Capsule, 10 mg, NDC 59762100401, Pedigree: AD52778_55, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PERPHENAZINE, Tablet, 8 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00630506221.

Batch or Lot Expiration Information

Lot# PERPHENAZINE, Tablet, 8 mg has the following codes: Pedigree: AD54605_1, EXP: 4/30/2014.

Recall Number: D-787-2014

Reason for Recall
Labeling: Label Mixup: CALCITRIOL, Capsule, 0.25 mcg may be potentially as one of the following drugs: ANAGRELIDE HCL, Capsule, 0.5 mg, NDC 00172524160, Pedigree: AD46414_7, EXP: 5/16/2014; BENAZEPRIL HCL, Tablet, 5 mg, NDC 65162075110, Pedigree: AD52778_7, EXP: 5/20/2014; CINACALCET HCL, Tablet, 30 mg, NDC 55513007330, Pedigree: W003615, EXP: 6/25/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
400 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CALCITRIOL, Capsule, 0.25 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054000725.

Batch or Lot Expiration Information

Lot# CALCITRIOL, Capsule, 0.25 mcg has the following codes: Pedigree: AD46414_10, EXP: 5/16/2014; Pedigree: AD52778_13, EXP: 5/20/2014; Pedigree: W003638, EXP: 6/25/2014.

Recall Number: D-769-2014

Reason for Recall
Labeling: Label Mixup: RALOXIFENE HCL, Tablet, 60 mg may be potentially mis-labeled as following drug: ISOSORBIDE MONONITRATE, Tablet, 20 mg, NDC 62175010701; Pedigree: W002656, EXP: 6/4/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
RALOXIFENE HCL, Tablet, 60 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00002416530.

Batch or Lot Expiration Information

Lot# RALOXIFENE HCL, Tablet, 60 mg has the following codes: Pedigree: W002644, EXP: 6/5/2014.

Recall Number: D-909-2014

Reason for Recall
Labeling: Label Mixup: FENOFIBRATE, Tablet, 54 mg may have potentially been mislabeled as one of the following drugs: LUBIPROSTONE, Capsule, 24 MCG, NDC 64764024060, Pedigree: AD21790_46, EXP: 5/1/2014; aMILoride HCl, Tablet, 5 mg, NDC 64980015101, Pedigree: AD60272_55, EXP: 5/22/2014; PROPRANOLOL HCL, Tablet, 10 mg, NDC 23155011001, Pedigree: W002732, EXP: 6/6/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
270 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FENOFIBRATE, Tablet, 54 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378710077.

Batch or Lot Expiration Information

Lot# FENOFIBRATE, Tablet, 54 mg has the following codes: Pedigree: AD21790_52, EXP: 5/1/2014; Pedigree: AD60272_64, EXP: 5/22/2014; Pedigree: W002733, EXP: 6/6/2014.

Recall Number: D-870-2014

Reason for Recall
Labeling: Label Mixup: ANAGRELIDE HCL, Capsule, 0.5 mg may have potentially been mislabeled as the following drug: ARIPiprazole, Tablet, 2 mg, NDC 59148000613, Pedigree: AD46414_1, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ANAGRELIDE HCL, Capsule, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00172524160.

Batch or Lot Expiration Information

Lot# ANAGRELIDE HCL, Capsule, 0.5 mg has the following codes: Pedigree: AD46414_7, EXP: 5/16/2014.

Recall Number: D-1025-2014

Reason for Recall
Labeling: Label Mixup: ASPIRIN EC, Tablet, 325 mg may have potentially been mislabeled as one of the following drugs: MULTIVITAMIN/MULTIMINERAL, CHEW Tablet, 0 mg, NDC 58914001460, Pedigree: AD30180_10, EXP: 5/9/2014; DILTIAZEM HCL ER, Capsule, 240 mg, NDC 49884083109, Pedigree: AD52375_1, EXP: 5/17/2014; ASPIRIN, Tablet, 325 mg, NDC 00536330501, Pedigree: W003355, EXP: 6/19/2014; ASPIRIN, Tab
Initiated
07-02-2013
Reported
01-29-2014
Quantity
499 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASPIRIN EC, Tablet, 325 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904201360.

Batch or Lot Expiration Information

Lot# ASPIRIN EC, Tablet, 325 mg has the following codes: Pedigree: AD30180_13, EXP: 5/9/2014; Pedigree: AD52378_1, EXP: 5/17/2014; Pedigree: W003356, EXP: 6/19/2014; Pedigree: W003526, EXP: 6/21/2014; Pedigree: AD39588_1, EXP: 5/13/2014.

Recall Number: D-849-2014

Reason for Recall
Labeling: Label Mixup: IRBESARTAN, Tablet, 150 mg may have potentially been mislabeled as the following drug: BENAZEPRIL HCL, Tablet, 40 mg, NDC 65162075410, Pedigree: AD32757_7, EXP: 5/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
IRBESARTAN, Tablet, 150 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093746556.

Batch or Lot Expiration Information

Lot# IRBESARTAN, Tablet, 150 mg has the following codes: Pedigree: AD42592_7, EXP: 5/14/2014.

Recall Number: D-877-2014

Reason for Recall
Labeling: Label Mixup: MIDODRINE HCL, Tablet, 2.5 mg may have potentially been mislabeled as the following drug: PIOGLITAZONE HCL, Tablet, 15 mg, NDC 00093204856, Pedigree: W003264, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MIDODRINE HCL, Tablet, 2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00185004001.

Batch or Lot Expiration Information

Lot# MIDODRINE HCL, Tablet, 2.5 mg has the following codes: Pedigree: W003265, EXP: 6/17/2014.

Recall Number: D-886-2014

Reason for Recall
Labeling: Label Mixup: HYDROCHLOROTHIAZIDE, Tablet, 12.5 mg may have potentially been mislabeled as one of the following drugs: hydrALAZINE HCl, Tablet, 100 mg, NDC 23155000401, Pedigree: AD73652_4, EXP: 5/29/2014; CLINDAMYCIN HCL, Capsule, 300 mg, NDC 00591312001, Pedigree: AD67989_1, EXP: 5/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
HYDROCHLOROTHIAZIDE, Tablet, 12.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00228282011.

Batch or Lot Expiration Information

Lot# HYDROCHLOROTHIAZIDE, Tablet, 12.5 mg has the following codes: Pedigree: AD73652_7, EXP: 5/29/2014 Pedigree: AD67989_13, EXP: 5/28/2014

Recall Number: D-895-2014

Reason for Recall
Labeling: Label Mixup: guanFACINE HC, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: glyBURIDE, Tablet, 2.5 mg, NDC 00093834301, Pedigree: AD46265_22, EXP: 5/15/2014; FOSINOPRIL SODIUM, Tablet, 10 mg, NDC 60505251002, Pedigree: AD46414_19, EXP: 5/16/2014; chlorproMAZINE HCl, Tablet, 100 mg, NDC 00832030300, Pedigree: AD70629_4, EXP: 5/29/2014; guanFACINE HCl,
Initiated
07-02-2013
Reported
01-29-2014
Quantity
500 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
guanFACINE HC, Tablet, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378116001.

Batch or Lot Expiration Information

Lot# guanFACINE HC, Tablet, 1 mg has the following codes: Pedigree: AD46265_25, EXP: 5/15/2014; Pedigree: AD46414_22, EXP: 5/16/2014; Pedigree: AD70629_7, EXP: 5/29/2014; Pedigree: W003007, EXP: 6/12/2014.

Recall Number: D-817-2014

Reason for Recall
Labeling: Label Mixup: VALSARTAN, Tablet, 320 mg may have potentially been mislabeled as the following drug: CILOSTAZOL, Tablet, 100 mg, NDC 60505252201, Pedigree: AD65475_4, EXP: 5/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VALSARTAN, Tablet, 320 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078036034.

Batch or Lot Expiration Information

Lot# VALSARTAN, Tablet, 320 mg has the following codes: Pedigree: AD65475_7, EXP: 5/28/2014.

Recall Number: D-810-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 125 mcg may have potentially been mislabeled as the following drug: MAGNESIUM CHLORIDE DR, Tablet, 64 mg, NDC 00904791152, Pedigree: AD70615_1, EXP: 2/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 125 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00074706890.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 125 mcg has the following codes: Pedigree: AD70633_4, EXP: 5/23/2014.

Recall Number: D-784-2014

Reason for Recall
Labeling: Label Mixup: PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units may be potentially mislabeled as the following drug: ASPIRIN/ER DIPYRIDAMOLE, Capsule, 25 mg/200 mg, NDC 00597000160, Pedigree: AD70639_4, EXP: 7/28/2013.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
12 months

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units, Rx only, Distributed by: AidaPak Service, LLC, NDC 00032121207.

Batch or Lot Expiration Information

Lot# PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units has the following codes: Pedigree: AD70639_7, EXP: 5/29/2014.

Recall Number: D-1010-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 137 mcg may have potentially been mislabeled as the following drug: OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 40985022921, Pedigree: AD21846_1, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 137 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781519192.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 137 mcg has the following codes: Pedigree: AD22616_10, EXP: 5/2/2014.

Recall Number: D-974-2014

Reason for Recall
Labeling: Label Mixup:TRIHEXYPHENIDYL HCL, Tablet, 1 mg (1/2 of 2 mg) may have potentially been mislabeled as the following drug: PERPHENAZINE, Tablet, 16 mg, NDC 00781104901, Pedigree: AD73525_22, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TRIHEXYPHENIDYL HCL, Tablet, 1 mg (1/2 of 2 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00591533501.

Batch or Lot Expiration Information

Lot# TRIHEXYPHENIDYL HCL, Tablet, 1 mg (1/2 of 2 mg) has the following codes: Pedigree: AD73525_34, EXP: 5/30/2014.

Recall Number: D-883-2014

Reason for Recall
Labeling: Label Mixup: SODIUM CHLORIDE, Tablet, 1 mg may have potentially been mislabeled as one of the following drugs: BISACODYL EC, Tablet, 5 mg, NDC 00904792760, Pedigree: AD34931_1, EXP: 5/9/2014; DUTASTERIDE, Capsule, 0.5 mg, NDC 00173071215, Pedigree: AD70633_1, EXP: 5/29/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 00904404360, Pedigree: W002509, EXP: 6/3/2014; SODIUM CHLORIDE, Tabl
Initiated
07-02-2013
Reported
01-29-2014
Quantity
7891 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SODIUM CHLORIDE, Tablet, 1 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00223176001.

Batch or Lot Expiration Information

Lot# SODIUM CHLORIDE, Tablet, 1 mg has the following codes: Pedigree: AD39560_1, EXP: 5/13/2014; Pedigree: AD70636_1, EXP: 5/29/2014; Pedigree: AD73662_1, EXP: 6/3/2014; Pedigree: W002611, EXP: 6/4/2014; Pedigree: W003792, EXP: 6/27/2014; Pedigree: AD22845_10, EXP: 5/2/2014; Pedigree: W003115, EXP: 6/13/2014; Pedigree: W003707, EXP: 6/25/2014.

Recall Number: D-893-2014

Reason for Recall
Labeling: Label Mixup: tiZANidine HCl, Tablet, 2 mg may have potentially been mislabeled as the following drug: NIACIN TR, Tablet, 500 mg, NDC 00904434260, Pedigree: W002969, EXP: 6/11/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
150 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
tiZANidine HCl, Tablet, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378072219.

Batch or Lot Expiration Information

Lot# tiZANidine HCl, Tablet, 2 mg has the following codes: Pedigree: W002975, EXP: 6/11/2014.

Recall Number: D-951-2014

Reason for Recall
Labeling: Label Mixup: hydrOXYzine PAMOATE, Capsule, 100 mg may have potentially been mislabeled as one of the following drugs: CALCIUM CITRATE, Tablet, 950 mg (200 mg Elemental Calcium), NDC 00904506260, AD46257_43, EXP: 5/15/2014; guaiFENesin ER, Tablet, 600 mg, NDC 45802049878, Pedigree: W002734, EXP: 6/6/2014; guaiFENesin ER, Tablet, 600 mg, NDC 45802049878, Pedigree: W003689, EXP: 6/26/20
Initiated
07-02-2013
Reported
01-29-2014
Quantity
800 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
hydrOXYzine PAMOATE, Capsule, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00555032402.

Batch or Lot Expiration Information

Lot# hydrOXYzine PAMOATE, Capsule, 100 mg has the following codes: Pedigree: AD46265_28, EXP: 5/15/2014; Pedigree: W002735, EXP: 6/6/2014; Pedigree: W003690, EXP: 6/26/2014; Pedigree: AD21790_61, EXP: 5/1/2014; Pedigree: AD60272_67, EXP: 5/22/2014; Pedigree: W003008, EXP: 6/11/2014; Pedigree: W003332, EXP: 6/18/2014.

Recall Number: D-859-2014

Reason for Recall
Labeling: Label Mixup: TERBUTALINE SULFATE, Tablet, 2.5 mg may have potentially been mislabeled as the following drug: SOTALOL HCL, Tablet, 80 mg, NDC 00093106101, Pedigree: AD52778_85, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
101 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TERBUTALINE SULFATE, Tablet, 2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00115261101.

Batch or Lot Expiration Information

Lot# TERBUTALINE SULFATE, Tablet, 2.5 mg has the following codes: Pedigree: AD52778_88, EXP: 5/21/2014.

Recall Number: D-891-2014

Reason for Recall
Labeling: Label Mixup: ATROPINE SULFATE/DIPHENOXYLATE HCL, Tablet, 0.025 mg/2.5 mg may have potentially been mislabeled as the following drug: CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00536355601, Pedigree: AD65475_25, EXP: 5/28/2014. TRI-BUFFERED ASPIRIN, Tablet, 325 mg, NDC 00904201559, Pedigree: W003581, EXP: 6/24/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATROPINE SULFATE/DIPHENOXYLATE HCL, Tablet, 0.025 mg/2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378041501.

Batch or Lot Expiration Information

Lot# ATROPINE SULFATE/DIPHENOXYLATE HCL, Tablet, 0.025 mg/2.5 mg has the following codes: Pedigree: AD65475_13, EXP: 5/28/2014; Pedigree: W003597, EXP: 6/24/2014.

Recall Number: D-767-2014

Reason for Recall
Labeling: Label Mixup: ATOMOXETINE HCL, Capsule, 18 mg, may be potentially mis-labeled as the following drug: LOVASTATIN, Tablet, 20 mg, NDC 00185007201, Pedigree: AD28369_1, EXP: 5/7/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATOMOXETINE HCL, Capsule, 18 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00002323830.

Batch or Lot Expiration Information

Lot# ATOMOXETINE HCL, Capsule, 18 mg has the following codes: Pedigree: AD30140_16, EXP: 5/7/2014.

Recall Number: D-773-2014

Reason for Recall
Labeling: Label Mixup: CALCIUM CARBONATE/CHOLECALCIFEROL, Tablet, 600 mg/800 units may be potentially mis-labeled as the following drug: REPAGLINIDE, Tablet, 1 mg, NDC 00169008281, Pedigree: AD52387_1, EXP: 5/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
120 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CALCIUM CARBONATE/CHOLECALCIFEROL, Tablet, 600 mg/800 units, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00005550924.

Batch or Lot Expiration Information

Lot# CALCIUM CARBONATE/CHOLECALCIFEROL, Tablet, 600 mg/800 units has the following codes: Pedigree: AD52993_1, EXP: 5/17/2014.

Recall Number: D-770-2014

Reason for Recall
Labeling: Label Mixup: ENTECAVIR, Tablet, 0.5 mg may be potentially mis-labeled as one of the following drugs: ARIPiprazole, Tablet, 2 mg, NDC 59148000613, Pedigree: AD30140_25, EXP: 5/7/2014; aMILoride HCl, Tablet, 5 mg, NDC 64980015101, Pedigree: W003686, EXP: 6/26/2014; ATOMOXETINE HCL, Capsule, 80 mg, NDC 00002325030, Pedigree: AD60272_49, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ENTECAVIR, Tablet, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00003161112.

Batch or Lot Expiration Information

Lot# ENTECAVIR, Tablet, 0.5 mg has the following codes: Pedigree: AD30140_28, EXP: 5/7/2014; Pedigree: W003687, EXP: 6/26/2014; Pedigree: AD60272_58. EXP: 5/22/2014.

Recall Number: D-825-2014

Reason for Recall
Labeling: Label Mixup: METOPROLOL TARTRATE, Tablet, 50 mg may have potentially been mislabeled as one of the following drugs: METOPROLOL TARTRATE, Tablet, 25 mg, NDC 57664050652, Pedigree: W003843, EXP: 6/27/2014; ATORVASTATIN CALCIUM, Tablet, 20 mg, NDC 60505257909, Pedigree: W003846, EXP: 6/27/2014; OXYBUTYNIN CHLORIDE, Tablet, 5 mg, NDC 00603497521, Pedigree: W003898, EXP: 6/27/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
METOPROLOL TARTRATE, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093073301.

Batch or Lot Expiration Information

Lot# METOPROLOL TARTRATE, Tablet, 50 mg has the following codes: Pedigree: W003844, EXP: 6/27/2014; Pedigree: W003848, EXP: 6/27/2014; Pedigree: W003900, EXP: 6/27/2014.

Recall Number: D-933-2014

Reason for Recall
Labeling: Label Mixup: CYANOCOBALAMIN, Tablet, 1000 mcg may have potentially been mislabeled as one of the following drugs: VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 50 mg, NDC 40985022251, Pedigree: AD30180_19, EXP: 5/9/2014; COENZYME Q-10, Capsule, 100 mg, NDC 37205055065, Pedigree: AD37056_4, EXP: 5/10/2014. VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 0, NDC 40985022251, Pedigree: AD7362
Initiated
07-02-2013
Reported
01-29-2014
Quantity
923 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CYANOCOBALAMIN, Tablet, 1000 mcg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536355601.

Batch or Lot Expiration Information

Lot# CYANOCOBALAMIN, Tablet, 1000 mcg may have potentially been mislabeled as one of the following drugs: VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 50 mg, NDC 40985022251, Pedigree: AD30180_19, EXP: 5/9/2014; COENZYME Q-10, Capsule, 100 mg, NDC 37205055065, Pedigree: AD37056_4, EXP: 5/10/2014. VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 0, NDC 40985022251, Pedigree: AD73627_26, EXP: 5/30/2014; PANCRELIPASE DR, Capsule, 24000 /76000 /120000 USP units, NDC 00032122401, Pedigree: W003856, EXP: 6/26/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 00904404360, Pedigree: W003052, EXP: 6/12/2014; VENLAFAXINE HCL, Tablet, 50 mg, NDC 23155024801, Pedigree: AD65475_22, EXP: 5/28/2014; CINACALCET HCL, Tablet, 30 mg, NDC 55513007330, Pedigree: AD32757_50, EXP: 5/14/2014.

Recall Number: D-954-2014

Reason for Recall
Labeling: Label Mixup: BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg may have potentially been mislabeled as one of the following drugs: BENAZEPRIL HCL, Tablet, 40 mg, NDC 65162075410, Pedigree: AD68010_1, EXP: 5/28/2014; THIORIDAZINE HCL, Tablet, 50 mg, NDC 00378061601, Pedigree: AD73525_28, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
63 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00574010603.

Batch or Lot Expiration Information

Lot# BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg has the following codes: Pedigree: AD68010_4, EXP: 5/28/2014; Pedigree: AD73525_40, EXP: 5/30/2014.

Recall Number: D-992-2014

Reason for Recall
Labeling: Label Mixup: PHENobarbital, Tablet, 97.2 mg may have potentially been mislabeled as the following drug: EFAVIRENZ, Capsule, 200 mg, NDC 00056047492, Pedigree: AD46312_31, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1000 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PHENobarbital, Tablet, 97.2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603516832.

Batch or Lot Expiration Information

Lot# PHENobarbital, Tablet, 97.2 mg has the following codes: Pedigree: AD46339_1, EXP: 5/16/2014.

Recall Number: D-897-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 88 mcg may have potentially been mislabeled as one of the following drugs: NEBIVOLOL HCL, Tablet, 5 mg, NDC 00456140530, Pedigree: AD73611_7, EXP: 5/30/2014; MELATONIN, Tablet, 3 mg, NDC 08770140813, Pedigree: W003022, EXP: 6/12/2014; ISOSORBIDE DINITRATE, Tablet, 5 mg, NDC 00781163501, Pedigree: W003474, EXP: 6/20/2014; HYDROCORTISONE, Tabl
Initiated
07-02-2013
Reported
01-29-2014
Quantity
600 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 88 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378180701.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 88 mcg has the following codes: Pedigree: AD73652_10, EXP: 5/30/2014; Pedigree: W003047, EXP: 6/12/2014; Pedigree: W003476, EXP: 6/20/2014; Pedigree: W002967, EXP: 6/11/2014; Pedigree: AD42584_1, EXP: 5/14/2014.

Recall Number: D-939-2014

Reason for Recall
Labeling: Label Mixup: CALCIUM POLYCARBOPHIL, Tablet, 625 mg may have potentially been mislabeled as the following drug: CAFFEINE, Tablet, 100 mg (1/2 of 200 mg), NDC 24385060173, Pedigree: ADWA00002146, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CALCIUM POLYCARBOPHIL, Tablet, 625 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536430611.

Batch or Lot Expiration Information

Lot# CALCIUM POLYCARBOPHIL, Tablet, 625 mg has the following codes: Pedigree: AD73592_11, EXP: 5/31/2014.

Recall Number: D-872-2014

Reason for Recall
Labeling: Label Mixup: DUTASTERIDE, Capsule, 0.5 mg may have potentially been mislabeled as one of the following drugs: DOCUSATE SODIUM, Capsule, 250 mg, NDC 00536375701, Pedigree: AD65457_19, EXP: 5/24/2014; DOCUSATE SODIUM, Capsule, 250 mg, NDC 00904789159, Pedigree: AD56924_1, EXP: 5/21/2014; PYRIDOXINE HCL, Tablet, 50 mg, NDC 00904052060, Pedigree: W003257, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
270 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DUTASTERIDE, Capsule, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00173071204.

Batch or Lot Expiration Information

Lot# DUTASTERIDE, Capsule, 0.5 mg has the following codes: Pedigree: AD65475_1, EXP: 5/28/2014; Pedigree: AD54519_1, EXP: 5/21/2014; Pedigree: W003247, EXP: 6/17/2014.

Recall Number: D-771-2014

Reason for Recall
Labeling: Label Mixup: MYCOPHENOLATE MOFETIL, Capsule, 250 mg may be potentially mis-labeled as the following drug: CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: AD52412_11, EXP: 5/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MYCOPHENOLATE MOFETIL, Capsule, 250 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00004025901.

Batch or Lot Expiration Information

Lot# MYCOPHENOLATE MOFETIL, Capsule, 250 mg has the following codes: Pedigree: AD49414_1, EXP: 5/17/2014.

Recall Number: D-980-2014

Reason for Recall
Labeling: Label Mixup: ASPIRIN/ER DIPYRIDAMOLE, Capsule, 25 mg/200 mg may have potentially been mislabeled as the following drug: THIAMINE HCL, Tablet, 100 mg, NDC 00904054460, Pedigree: AD70639_1, EXP: 5/29/2014; LEVOTHYROXINE SODIUM, Tablet, 88 mcg, NDC 00781518392, Pedigree: W003439, EXP: 6/20/2014; ZINC SULFATE, Capsule, 220 mg, NDC 60258013101, Pedigree: W003641, EXP: 6/25/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
300 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASPIRIN/ER DIPYRIDAMOLE, Capsule, 25 mg/200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00597000160.

Batch or Lot Expiration Information

Lot# ASPIRIN/ER DIPYRIDAMOLE, Capsule, 25 mg/200 mg has the following codes: Pedigree: AD70639_4, EXP: 7/28/2013; Pedigree: W003468, EXP: 8/19/2013; Pedigree: W003644, EXP: 8/24/2013.

Recall Number: D-957-2014

Reason for Recall
Labeling: Label Mixup: LIOTHYRONINE SODIUM, Tablet, 25 mcg may have potentially been mislabeled as one of the following drugs: LEVOTHYROXINE SODIUM, Tablet, 175 mcg, NDC 00378181701, Pedigree: W003151, EXP: 6/13/2014; HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, NDC 00574025001, Pedigree: W003000, EXP: 6/11/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LIOTHYRONINE SODIUM, Tablet, 25 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00574022201.

Batch or Lot Expiration Information

Lot# LIOTHYRONINE SODIUM, Tablet, 25 mcg has the following codes: Pedigree: W003152, EXP: 4/30/2014; Pedigree: W003001, EXP: 4/30/2014.

Recall Number: D-793-2014

Reason for Recall
Labeling: Label Mixup: EXEMESTANE, Tablet, 25 mg may be potentially mislabeled as the following drug: OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 00904404360, Pedigree: W003473, EXP: 6/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
EXEMESTANE, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054008013.

Batch or Lot Expiration Information

Lot# EXEMESTANE, Tablet, 25 mg has the following codes: Pedigree: W003471, EXP: 6/20/2014.

Recall Number: D-853-2014

Reason for Recall
Labeling: Label Mixup: glyBURIDE, Tablet, 1.25 mg may have potentially been mislabeled as one of the following drugs: CYPROHEPTADINE HCL, Tablet, 4 mg, NDC 60258085001, Pedigree: W003676, EXP: 6/25/2014; AMANTADINE HCL, Capsule, 100 mg, NDC 00781204801, Pedigree: AD21790_1, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
glyBURIDE, Tablet, 1.25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093834201.

Batch or Lot Expiration Information

Lot# glyBURIDE, Tablet, 1.25 mg has the following codes: Pedigree: W003677, EXP: 2/28/2014; Pedigree: AD21790_10, EXP: 2/28/2014.

Recall Number: D-874-2014

Reason for Recall
Labeling: Label Mixup: OMEGA-3-ACID ETHYL ESTERS, Capsule, 1000 mg may have potentially been mislabeled as one of the following drugs: SEVELAMER CARBONATE, Tablet, 800 mg, NDC 58468013001, Pedigree: AD39858_4, EXP: 5/15/2014; hydrOXYzine PAMOATE, Capsule, 100 mg, NDC 00555032402, Pedigree: W002735, EXP: 6/6/2014; PROPRANOLOL HCL, Tablet, 10 mg, NDC 23155011001, Pedigree: W003229, EXP: 6/17/2014
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1439 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
OMEGA-3-ACID ETHYL ESTERS, Capsule, 1000 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00173078302.

Batch or Lot Expiration Information

Lot# OMEGA-3-ACID ETHYL ESTERS, Capsule, 1000 mg has the following codes: Pedigree: AD46265_43, EXP: 5/15/2014; Pedigree: W002736, EXP: 6/6/2014; Pedigree: W003243, EXP: 6/17/2014; Pedigree: W003692, EXP: 6/26/2014; Pedigree: AD32757_40, EXP: 5/14/2014; Pedigree: W003011, EXP: 6/12/2014; Pedigree: W003333, EXP: 6/19/2014.

Recall Number: D-1028-2014

Reason for Recall
Labeling: Label Mixup: NIACIN, Tablet, 500 mg may have potentially been mislabeled as one of the following drugs: NAPROXEN, Tablet, 500 mg, NDC 53746019001, Pedigree: AD54516_1, EXP: 5/20/2014; DOCUSATE SODIUM, Capsule, 250 mg, NDC 00904789159, Pedigree: W002920, EXP: 6/10/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIACIN, Tablet, 500 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904227260.

Batch or Lot Expiration Information

Lot# NIACIN, Tablet, 500 mg has the following codes: Pedigree: AD52993_10, EXP: 5/20/2014; Pedigree: W002957, EXP: 6/10/2014.

Recall Number: D-1006-2014

Reason for Recall
Labeling: Label Mixup: TACROLIMUS, Capsule, 0.5 mg may have potentially been mislabeled as one of the following drugs: CINACALCET HCL, Tablet, 30 mg, NDC 55513007330, Pedigree: W003168, EXP: 6/13/2014; ISOSORBIDE MONONITRATE ER, Tablet, 30 mg, NDC 62175012837, Pedigree: W003350, EXP: 6/18/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TACROLIMUS, Capsule, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781210201.

Batch or Lot Expiration Information

Lot# TACROLIMUS, Capsule, 0.5 mg has the following codes: Pedigree: W003169, EXP: 6/13/2014; Pedigree: W003351, EXP: 6/18/2014.

Recall Number: D-776-2014

Reason for Recall
Labeling: Label Mixup: MONTELUKAST SODIUM, CHEW Tablet, 4 mg may be potentially mislabeled as the following drug: DICYCLOMINE HCL, Tablet, 20 mg, NDC 00591079501, Pedigree: AD76639_4, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 CHEW Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MONTELUKAST SODIUM, CHEW Tablet, 4 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00006071131.

Batch or Lot Expiration Information

Lot# MONTELUKAST SODIUM, CHEW Tablet, 4 mg has the following codes: Pedigree: AD76639_11, EXP: 5/31/2014.

Recall Number: D-820-2014

Reason for Recall
Labeling: Label Mixup: carBAMazepine ER, Tablet, 100 mg may have potentially been mislabeled as one of the following drugs: ISOSORBIDE DINITRATE ER, Tablet, 40 mg, NDC 57664060088, Pedigree: AD23082_4, EXP: 5/3/2014; SIROLIMUS, Tablet, 1 mg, NDC 00008104105, Pedigree: W003329, EXP: 6/18/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
carBAMazepine ER, Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078051005.

Batch or Lot Expiration Information

Lot# carBAMazepine ER, Tablet, 100 mg has the following codes: Pedigree: AD30140_22, EXP: 5/7/2014; Pedigree:W003330, EXP: 6/18/2014.

Recall Number: D-854-2014

Reason for Recall
Labeling: Label Mixup: glyBURIDE, Tablet, 2.5 mg may have potentially been mislabeled as one of the following drugs: sulfaSALAzine, Tablet, 500 mg, NDC 59762500001, Pedigree: AD46265_13, EXP: 5/15/2014; ENTECAVIR, Tablet, 0.5 mg, NDC 00003161112, Pedigree: W003687, EXP: 6/26/2014; RALTEGRAVIR, Tablet, 400 mg, NDC 00006022761, Pedigree: AD21790_22, EXP: 5/1/2014; carBAMazepine ER, Tablet, 100 m
Initiated
07-02-2013
Reported
01-29-2014
Quantity
500 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
glyBURIDE, Tablet, 2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093834301.

Batch or Lot Expiration Information

Lot# glyBURIDE, Tablet, 2.5 mg has the following codes: Pedigree: AD46265_22, EXP: 5/15/2014; Pedigree: W003688, EXP: 5/31/2014; Pedigree: AD21790_55, EXP: 5/1/2014; Pedigree: AD30140_34, EXP: 5/7/2014.

Recall Number: D-987-2014

Reason for Recall
Labeling: Label Mixup: OXYBUTYNIN CHLORIDE, Tablet, 2.5 mg (1/2 of 5 mg) may have potentially been mislabeled as the following drug: PIMOZIDE, Tablet, 1 mg (1/2 of 2 mg), NDC 57844018701, Pedigree: AD73525_61, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
199 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
OXYBUTYNIN CHLORIDE, Tablet, 2.5 mg (1/2 of 5 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00603497521

Batch or Lot Expiration Information

Lot# OXYBUTYNIN CHLORIDE, Tablet, 2.5 mg (1/2 of 5 mg) has the following codes: Pedigree: AD73525_64, EXP: 5/30/2014.

Recall Number: D-964-2014

Reason for Recall
Labeling: Label Mixup: TRIAMTERENE/ HYDROCHLOROTHIAZIDE, Tablet, 37.5 mg/25 mg may have potentially been mislabeled as the following drug: SEVELAMER HCL, Tablet 800 mg, NDC 58468002101, Pedigree: W002858, EXP: 6/7/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TRIAMTERENE/ HYDROCHLOROTHIAZIDE, Tablet, 37.5 mg/25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591042401.

Batch or Lot Expiration Information

Lot# TRIAMTERENE/ HYDROCHLOROTHIAZIDE, Tablet, 37.5 mg/25 mg has the following codes: Pedigree: W002900, EXP: 6/10/2014.

Recall Number: D-842-2014

Reason for Recall
Labeling: Label Mixup: SIMVASTATIN, Tablet, 40 mg may have potentially been mislabeled as the following drug: METOPROLOL TARTRATE, Tablet, 12.5 mg (1/2 of 25 mg), NDC 63304057901, Pedigree: AD21790_67, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SIMVASTATIN, Tablet, 40 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093715598.

Batch or Lot Expiration Information

Lot# SIMVASTATIN, Tablet, 40 mg has the following codes: Pedigree: AD22845_4, EXP: 5/2/2014.

Recall Number: D-901-2014

Reason for Recall
Labeling: Label Mixup: ATORVASTATIN CALCIUM, Tablet, 20 mg may have potentially been mislabeled as one of the following drugs: COENZYME Q-10, Capsule, 100 mg, NDC 37205055065, Pedigree: AD32325_4, EXP: 5/9/2014; ATORVASTATIN CALCIUM, Tablet, 10 mg, NDC 00378201577, Pedigree: AD49582_7, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
811 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATORVASTATIN CALCIUM, Tablet, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378201777.

Batch or Lot Expiration Information

Lot# ATORVASTATIN CALCIUM, Tablet, 20 mg has the following codes: Pedigree: AD33897_7, EXP: 5/9/2014; Pedigree: AD49582_10, EXP: 5/16/2014.

Recall Number: D-917-2014

Reason for Recall
Labeling: Label Mixup: POTASSIUM ACID PHOSPHATE, Tablet, 500 mg may have potentially been mislabeled as the following drug: predniSONE, Tablet, 20 mg, NDC 00591544301, Pedigree: AD56879_5, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
POTASSIUM ACID PHOSPHATE, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00486111101.

Batch or Lot Expiration Information

Lot# POTASSIUM ACID PHOSPHATE, Tablet, 500 mg has the following codes: Pedigree: AD52778_34, EXP: 5/20/2014.

Recall Number: D-873-2014

Reason for Recall
Labeling: Label Mixup: DUTASTERIDE, Capsule, 0.5 mg may have potentially been mislabeled as one of the following drugs: PHENOL, LOZENGE, 29 mg, NDC 00068021918, Pedigree: AD49582_13, EXP: 5/16/2014; REPAGLINIDE, Tablet, 2 mg, NDC 00169008481, Pedigree: AD70639_13, EXP: 5/29/2014; CHOLECALCIFEROL, Capsule, 5000 units, NDC 00904598660, Pedigree: AD52993_22, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DUTASTERIDE, Capsule, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00173071215.

Batch or Lot Expiration Information

Lot# DUTASTERIDE, Capsule, 0.5 mg has the following codes: Pedigree: AD49610_1, EXP: 5/16/2014; Pedigree: AD70633_1, EXP: 5/29/2014; Pedigree: AD52778_4, EXP: 5/20/2014.

Recall Number: D-902-2014

Reason for Recall
Labeling: Label Mixup: ATORVASTATIN CALCIUM, Tablet, 40 mg may have potentially been mislabeled as one of the following drugs: ATORVASTATIN CALCIUM, Tablet, 10 mg, NDC 00378201577, Pedigree: AD33897_4, EXP: 5/9/2014; FINASTERIDE, Tablet, 5 mg, NDC 16714052201, Pedigree: W003031, EXP: 2/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
810 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATORVASTATIN CALCIUM, Tablet, 40 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378212177 .

Batch or Lot Expiration Information

Lot# ATORVASTATIN CALCIUM, Tablet, 40 mg has the following codes: Pedigree: AD33897_10, EXP: 5/9/2014; Pedigree: W003096, EXP: 6/13/2014.

Recall Number: D-900-2014

Reason for Recall
Labeling: Label Mixup: ATORVASTATIN CALCIUM, Tablet, 10 mg may have potentially been mislabeled as one of the following drugs: PANCRELIPASE DR, Capsule, 12000 /38000 /60000 USP units, NDC 00032121201, Pedigree: AD30180_4, EXP: 5/8/2014; OMEPRAZOLE/SODIUM BICARBONATE, Capsule, 20 mg/1,110 mg, NDC 11523726503, Pedigree: AD49399_4, EXP: 5/16/2014; ASPIRIN, CHEW Tablet, 81 mg, NDC 00536329736, Pedi
Initiated
07-02-2013
Reported
01-29-2014
Quantity
990 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATORVASTATIN CALCIUM, Tablet, 10 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378201577.

Batch or Lot Expiration Information

Lot# ATORVASTATIN CALCIUM, Tablet, 10 mg has the following codes: Pedigree: AD33897_4, EXP: 5/9/2014; Pedigree: AD49582_7, EXP: 5/16/2014; Pedigree: W002774, EXP: 6/6/2014; Pedigree: W003095, EXP: 6/12/2014

Recall Number: D-814-2014

Reason for Recall
Labeling: Label Mixup: FLUVASTATIN SODIUM, Capsule, 20 mg may have potentially been mislabeled as the following drug: VALSARTAN, Tablet, 80 mg, NDC 00078035834, Pedigree: AD73597_1, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FLUVASTATIN SODIUM, Capsule, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078017615.

Batch or Lot Expiration Information

Lot# FLUVASTATIN SODIUM, Capsule, 20 mg has the following codes: Pedigree: AD73597_7, EXP: 5/31/2014.

Recall Number: D-918-2014

Reason for Recall
Labeling: Label Mixup: SODIUM CHLORIDE, Tablet, 1000 mg may have potentially been mislabeled as the following drug: REPAGLINIDE, Tablet, 2 mg, NDC 00169008481, Pedigree: W003925, EXP: 7/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1000 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SODIUM CHLORIDE, Tablet, 1000 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00527111610

Batch or Lot Expiration Information

Lot# SODIUM CHLORIDE, Tablet, 1000 mg has the following codes: Pedigree: W003925, EXP: 7/1/2014.

Recall Number: D-875-2014

Reason for Recall
Labeling: Label Mixup: ASPIRIN DR EC, Tablet, 81 mg may have potentially been mislabeled as one of the following drugs: SOTALOL HCL, Tablet, 120 mg, NDC 00093106001, Pedigree: AD49448_20, EXP: 5/17/2014; FOLIC ACID, Tablet, 1 mg, NDC 65162036110, Pedigree: W003097, EXP: 6/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1499 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASPIRIN DR EC, Tablet, 81 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00182106105.

Batch or Lot Expiration Information

Lot# ASPIRIN DR EC, Tablet, 81 mg has the following codes: Pedigree: AD52433_1, EXP: 5/17/2014; Pedigree: W003094, EXP: 6/13/2014.

Recall Number: D-887-2014

Reason for Recall
Labeling: Label Mixup: ROSUVASTATIN CALCIUM, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: IBUPROFEN, Tablet, 400 mg, NDC 67877029401, Pedigree: W002577, EXP: 6/3/2014; ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: AD21846_49, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
180 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ROSUVASTATIN CALCIUM, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00310075590.

Batch or Lot Expiration Information

Lot# ROSUVASTATIN CALCIUM, Tablet, 5 mg has the following codes: Pedigree: W002567, EXP: 6/3/2014; Pedigree: AD21811_10, EXP: 5/2/2014.

Recall Number: D-1021-2014

Reason for Recall
Labeling: Label Mixup: ASCORBIC ACID, CHEW Tablet, 500 mg may have potentially been mislabeled as the following drug: PHENOL, LOZENGE, 29 mg, NDC 00068021918, Pedigree: AD60428_4, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 CHEW Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASCORBIC ACID, CHEW Tablet, 500 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904052660.

Batch or Lot Expiration Information

Lot# ASCORBIC ACID, CHEW Tablet, 500 mg has the following codes: Pedigree: AD60240_54, EXP: 5/22/2014.

Recall Number: D-766-2014

Reason for Recall
Labeling: Label Mixup: DULoxetine HCl DR, Capsule, 20 mg, may be potentially mis-labeled with one of the following drugs: ENTECAVIR, Tablet, 0.5 mg, NDC 00003161112, Pedigree: AD30140_28, EXP: 5/7/2014; CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: AD54587_1, EXP: 5/21/2014; FLUoxetine HCl, Capsule, 10 mg , NDC 16714035103, Pedigree: AD70585_13, EXP: 5/29/2014; CHOLECALCIFEROL
Initiated
07-02-2013
Reported
01-29-2014
Quantity
600 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DULoxetine HCl DR, Capsule, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00002323560.

Batch or Lot Expiration Information

Lot# DULoxetine HCl DR, Capsule, 20 mg has the following codes: Pedigree: AD30140_31, EXP: 5/7/2014; Pedigree: AD54587_4, EXP: 5/21/2014; Pedigree: AD70585_16, EXP: 5/29/2014; Pedigree: W003506, EXP: 6/21/2014; Pedigree: AD60272_61, EXP: 5/22/2014; Pedigree: AD21790_49, EXP: 5/1/2014; Pedigree: W003005, EXP: 6/11/2014; Pedigree: W003486, EXP: 6/20/2014.

Recall Number: D-789-2014

Reason for Recall
Labeling: Label Mixup: LITHIUM CARBONATE ER, Tablet, 225 mg (1/2 of 450 mg) may be potentially mislabled as one of the following drugs: CYCLOBENZAPRINE HCL, Tablet, 5 mg, NDC 00591325601, Pedigree: AD73525_7, EXP: 5/30/2014; DOCUSATE SODIUM, Capsule, 250 mg, NDC 00536375710, Pedigree: AD21846_11, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
400 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LITHIUM CARBONATE ER, Tablet, 225 mg (1/2 of 450 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00054002025.

Batch or Lot Expiration Information

Lot# LITHIUM CARBONATE ER, Tablet, 225 mg (1/2 of 450 mg) has the following codes: Pedigree: AD73525_16, EXP: 5/30/2014; Pedigree: AD21790_25, EXP: 5/1/2014.

Recall Number: D-931-2014

Reason for Recall
Labeling: Label Mixup: CYANOCOBALAMIN, Tablet, 100 mcg may have potentially been mislabeled as the following drug: guaiFENesin ER, Tablet, 600 mg, NDC 63824000834, Pedigree: AD62834_7, EXP: 5/24/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
99 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CYANOCOBALAMIN, Tablet, 100 mcg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536354201.

Batch or Lot Expiration Information

Lot# CYANOCOBALAMIN, Tablet, 100 mcg has the following codes: Pedigree: AD62840_1, EXP: 5/24/2014.

Recall Number: D-889-2014

Reason for Recall
Labeling: Label Mixup: CHLORTHALIDONE, Tablet, 50 mg may have potentially been mislabeled as the following drug: SENNOSIDES, Tablet, 8.6 mg, NDC 00182109301, Pedigree: W002979, EXP: 6/11/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CHLORTHALIDONE, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378021301.

Batch or Lot Expiration Information

Lot# CHLORTHALIDONE, Tablet, 50 mg has the following codes: Pedigree: W002988, EXP: 6/11/2014.

Recall Number: D-811-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 175 mcg may have potentially been mislabeled as the following drug: CINACALCET HCL, Tablet, 60 mg, NDC 55513007430, Pedigree: W003742, EXP: 6/26/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 175 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00074707090.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 175 mcg has the following codes: Pedigree: W003743, EXP: 6/26/2014.

Recall Number: D-852-2014

Reason for Recall
Labeling: Label Mixup: DOXAZOSIN MESYLATE, Tablet, 1 mg may have potentially been mislabeled as the following drug: PYRIDOXINE HCL, Tablet, 100 mg, NDC 00536440901, Pedigree: W003872, EXP: 6/27/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DOXAZOSIN MESYLATE, Tablet, 1 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00093812001.

Batch or Lot Expiration Information

Lot# DOXAZOSIN MESYLATE, Tablet, 1 mg has the following codes: Pedigree: W003912, EXP: 6/28/2014.

Recall Number: D-840-2014

Reason for Recall
Labeling: Label Mixup: NEFAZODONE HCL, Tablet, 150 mg may have potentially been mislabeled as the following drug: LIOTHYRONINE SODIUM, Tablet, 25 mcg, NDC 42794001902, Pedigree: AD46414_35, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NEFAZODONE HCL, Tablet, 150 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093711306.

Batch or Lot Expiration Information

Lot# NEFAZODONE HCL, Tablet, 150 mg has the following codes: Pedigree: AD46414_41, EXP: 5/16/2014.

Recall Number: D-828-2014

Reason for Recall
Labeling: Label Mixup: NORTRIPTYLINE HCL, Capsule, 50 mg may have potentially been mislabeled as one of the following drugs: ROSUVASTATIN CALCIUM, Tablet, 5 mg, NDC 00310075590, Pedigree: AD21811_10, EXP: 5/2/2014; LIOTHYRONINE SODIUM, Tablet, 5 mcg, NDC 42794001802, Pedigree: AD46414_38, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NORTRIPTYLINE HCL, Capsule, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093081201.

Batch or Lot Expiration Information

Lot# NORTRIPTYLINE HCL, Capsule, 50 mg has the following codes: Pedigree: AD21790_70, EXP: 5/1/2014; Pedigree: AD46414_47, EXP: 5/16/2014.

Recall Number: D-985-2014

Reason for Recall
Labeling: Label Mixup: methylPREDNISolone, Tablet, 4 mg may have potentially been mislabeled as the following drug: OMEPRAZOLE/SODIUM BICARBONATE, Capsule, 20 mg/110 mg, NDC 11523726503, Pedigree: AD42584_15, EXP: 5/14/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
299 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
methylPREDNISolone, Tablet, 4 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603459321.

Batch or Lot Expiration Information

Lot# methylPREDNISolone, Tablet, 4 mg may have potentially been mislabeled as the following drug: OMEPRAZOLE/SODIUM BICARBONATE, Capsule, 20 mg/110 mg, NDC 11523726503, Pedigree: AD42584_15, EXP: 5/14/2014.

Recall Number: D-958-2014

Reason for Recall
Labeling: Label Mixup: HYOSCYAMINE SULFATE ODT, Tablet, 0.125 mg may have potentially been mislabeled as the following drug: FLUoxetine HCl, Capsule, 10 mg, NDC 16714035103, Pedigree: W003613, EXP: 6/25/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
101 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
HYOSCYAMINE SULFATE ODT, Tablet, 0.125 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00574024701.

Batch or Lot Expiration Information

Lot# HYOSCYAMINE SULFATE ODT, Tablet, 0.125 mg has the following codes: Pedigree: W003614, EXP: 6/25/2014.

Recall Number: D-1015-2014

Reason for Recall
Labeling: Label Mixup: chlorproMAZINE HCl, Tablet, 100 mg may have potentially been mislabeled as one of the following drugs: ACYCLOVIR, Tablet, 800 mg, NDC 00093894701, Pedigree: AD70629_1, EXP: 5/29/2014; TRIMETHOBENZAMIDE HCL, Capsule, 300 mg, NDC 53489037601, Pedigree: AD70625_1, EXP: 5/29/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
chlorproMAZINE HCl, Tablet, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00832030300.

Batch or Lot Expiration Information

Lot# chlorproMAZINE HCl, Tablet, 100 mg has the following codes: Pedigree: AD70629_4, EXP: 5/29/2014; Pedigree: AD70700_1, EXP: 5/29/2014.

Recall Number: D-911-2014

Reason for Recall
Labeling: Label Mixup: SACCHAROMYCES BOULARDII LYO, Capsule, 250 mg may have potentially been mislabeled as one of the following drugs: PREGABALIN, Capsule, 200 mg, NDC 00071101768, Pedigree: AD21787_1, EXP: 5/1/2014; HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, NDC 76439030910, Pedigree: AD54501_1, EXP: 5/21/2014; VARENICLINE, Tablet, 0.5 mg, NDC 00069046856, Pedigree: W003083, EXP: 6/12/2014; L
Initiated
07-02-2013
Reported
01-29-2014
Quantity
2024 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SACCHAROMYCES BOULARDII LYO, Capsule, 250 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00414200007.

Batch or Lot Expiration Information

Lot# SACCHAROMYCES BOULARDII LYO, Capsule, 250 mg has the following codes: Pedigree: AD21859_1, EXP: 10/31/2013; Pedigree: AD54586_1, EXP: 5/21/2014; Pedigree: W003030, EXP: 6/12/2014; Pedigree: W003866, EXP: 6/27/2014; Pedigree: AD37063_7, EXP: 5/13/2014; Pedigree: W002917, EXP: 6/10/2014; Pedigree: AD54586_4, EXP: 5/21/2014.

Recall Number: D-765-2014

Reason for Recall
Labeling: Label Mixup: ATOMOXETINE HCL, Capsule, 40 mg may be potentially mis-labeled as OLANZAPINE, Tablet, 7.5 mg, NDC 60505311203, Pedigree: AD21790_76, EXP: 5/1/2014; ARIPiprazole, Tablet, 2 mg, NDC 59148000613, Pedigree: AD46265_19, EXP: 5/15/2014; OLANZapine, Tablet, 7.5 mg, NDC 55111016530, Pedigree: AD60272_79, EXP: 5/22/2014; OLANZapine, Tablet, 7.5 mg, NDC 55111016530, Pedigree: AD73
Initiated
07-02-2013
Reported
01-29-2014
Quantity
180 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ATOMOXETINE HCL, Capsule, 40 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00002322930.

Batch or Lot Expiration Information

Lot# ATOMOXETINE HCL, Capsule, 40 mg has the following codes: Pedigree: AD21790_82, EXP: 5/1/2014; Pedigree: AD46265_52, EXP: 5/15/2014; Pedigree: AD60272_89, EXP: 5/22/2014; Pedigree: AD73525_67, EXP: 5/30/2014; Pedigree: W003014, EXP: 6/11/2014.

Recall Number: D-781-2014

Reason for Recall
Labeling: Label Mixup: TOLTERODINE TARTRATE ER, Capsule, 4 mg may be potentially mislabeled as one of the following drugs: HYDRALAZINE HCL, Tablet, 25 mg, NDC 50111032701, Pedigree: AD49610_4, EXP: 5/16/2014; PRENATAL MULTIVITAMIN/ MULTIMINERAL, Tablet, 0 mg, NDC 51991056601, Pedigree: AD73597_1, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TOLTERODINE TARTRATE ER, Capsule, 4 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00009519101.

Batch or Lot Expiration Information

Lot# TOLTERODINE TARTRATE ER, Capsule, 4 mg has the following codes: Pedigree: AD49448_1, EXP: 5/17/2014; Pedigree: AD73686_1, EXP: 5/31/2014.

Recall Number: D-880-2014

Reason for Recall
Labeling: Label Mixup: NABUMETONE, Tablet, 500 mg may have potentially been mislabeled as the following drug: guaiFENesin ER, Tablet, 600 mg, NDC 63824000834, Pedigree: AD46429_1, EXP: 5/15/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NABUMETONE, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00185014501.

Batch or Lot Expiration Information

Lot# NABUMETONE, Tablet, 500 mg has the following codes: Pedigree: AD46426_4, EXP: 5/15/2014.

Recall Number: D-947-2014

Reason for Recall
Labeling: Label Mixup: VITAMIN B COMPLEX W/C, Tablet, 0 mg may have potentially been mislabeled as the following drug: CINACALCET HCL, Tablet, 30 mg, NDC 55513007330, Pedigree: AD54516_4, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VITAMIN B COMPLEX W/C, Tablet, 0 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536730001.

Batch or Lot Expiration Information

Lot# VITAMIN B COMPLEX W/C, Tablet, 0 mg has the following codes: Pedigree: AD52993_7, EXP: 5/20/2014.

Recall Number: D-978-2014

Reason for Recall
Labeling: Label Mixup: MINOCYCLINE HCL, Capsule, 50 mg may have potentially been mislabeled as the following drug: MINOXIDIL, Tablet, 2.5 mg, NDC 00591564201, Pedigree: AD52778_49, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MINOCYCLINE HCL, Capsule, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591569401.

Batch or Lot Expiration Information

Lot# MINOCYCLINE HCL, Capsule, 50 mg has the following codes: Pedigree: AD52778_46, EXP: 5/20/2014.

Recall Number: D-816-2014

Reason for Recall
Labeling: Label Mixup: VALSARTAN, Tablet, 160 mg may have potentially been mislabeled as one of the following drugs: PROGESTERONE, Capsule, 100 mg, NDC 00032170801, Pedigree: AD46320_1, EXP: 5/15/2014; CapsuleTOPRIL, Tablet, 6.25 mg (1/2 of 12.5 mg), NDC 00143117101, Pedigree: AD46312_4, EXP: 5/16/2014; MYCOPHENOLATE MOFETIL, Tablet, 500 mg, NDC 00004026001, Pedigree: AD49414_4, EXP: 5/17/2014;
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1260 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VALSARTAN, Tablet, 160 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078035934.

Batch or Lot Expiration Information

Lot# VALSARTAN, Tablet, 160 mg has the following codes: Pedigree: AD39858_1, EXP: 5/16/2014; Pedigree: AD46312_7, EXP: 5/16/2014; Pedigree: AD49414_7, EXP: 5/17/2014; Pedigree: W002767, EXP: 6/6/2014; Pedigree: W003534, EXP: 6/21/2014; Pedigree: W003639, EXP: 6/25/2014; Pedigree: W002851, EXP: 6/7/2014; Pedigree: AD62995_1, EXP: 5/28/2014; Pedigree: W002964, EXP: 6/11/2014.

Recall Number: D-981-2014

Reason for Recall
Labeling: Label Mixup: BISMUTH SUBSALICYLATE, CHEW Tablet, 262 mg may have potentially been mislabeled as the following drug: IRBESARTAN, Tablet, 150 mg, NDC 00093746556, Pedigree: AD42592_7, EXP: 5/14/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 CHEW Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
BISMUTH SUBSALICYLATE, CHEW Tablet, 262 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00603023516.

Batch or Lot Expiration Information

Lot# BISMUTH SUBSALICYLATE, CHEW Tablet, 262 mg has the following codes: Pedigree: AD42592_10, EXP: 5/14/2014.

Recall Number: D-805-2014

Reason for Recall
Labeling: Label Mixup: PREGABALIN, Capsule, 25 mg may have potentially been mislabeled as one of the following drugs: CHOLECALCIFEROL, Capsule, 2000 units, NDC 00536379001, Pedigree: W003713, EXP: 6/26/2014; glyBURIDE MICRONIZED, Tablet, 3 mg, NDC 00093803501, Pedigree: W003155, EXP: 6/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
180 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PREGABALIN, Capsule, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00071101268.

Batch or Lot Expiration Information

Lot# PREGABALIN, Capsule, 25 mg has the following codes: Pedigree: W003777, EXP: 6/26/2014; Pedigree: W003121, EXP:6/13/2014.

Recall Number: D-841-2014

Reason for Recall
Labeling: Label Mixup: SIMVASTATIN, Tablet, 5 mg may have potentially been mislabeled as the following drug: LOSARTAN POTASSIUM, Tablet, 25 mg, NDC 13668011390, Pedigree: AD65323_10, EXP: 5/29/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SIMVASTATIN, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093715298.

Batch or Lot Expiration Information

Lot# SIMVASTATIN, Tablet, 5 mg has the following codes: Pedigree: AD65323_13, EXP: 5/29/2014.

Recall Number: D-1027-2014

Reason for Recall
Labeling: Label Mixup: NIACIN, Tablet, 100 mg may have potentially been mislabeled as the following drug: guaiFENesin ER, Tablet, 600 mg, NDC 63824000815, Pedigree: W002660, EXP: 6/5/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIACIN, Tablet, 100 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904227160.

Batch or Lot Expiration Information

Lot# NIACIN, Tablet, 100 mg has the following codes: Pedigree: W002661, EXP: 6/5/2014.

Recall Number: D-967-2014

Reason for Recall
Labeling: Label Mixup: DICYCLOMINE HCL, Tablet, 20 mg may have potentially been mislabeled as the following drug: RAMIPRIL, Capsule, 2.5 mg, NDC 68180058901, Pedigree: AD76639_1, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DICYCLOMINE HCL, Tablet, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591079501.

Batch or Lot Expiration Information

Lot# DICYCLOMINE HCL, Tablet, 20 mg has the following codes: Pedigree: AD76639_4, EXP: 5/31/2014.

Recall Number: D-959-2014

Reason for Recall
Labeling: Label Mixup: HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg may have potentially been mislabeled as one of the following drugs: guanFACINE HCl, Tablet, 2 mg, NDC 65162071310, Pedigree: AD21790_13, EXP: 5/1/2014; CYCLOBENZAPRINE HCL, Tablet, 5 mg, NDC 00591325601, Pedigree: AD46265_4, EXP: 5/15/2014; guanFACINE HCl, Tablet, 2 mg, NDC 65162071310, Pedigree: W003678, EXP: 6/25/2014; guanFACIN
Initiated
07-02-2013
Reported
01-29-2014
Quantity
909 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00574025001.

Batch or Lot Expiration Information

Lot# HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg has the following codes: Pedigree: AD21790_19, EXP: 5/1/2014; Pedigree: AD46265_7, EXP: 5/15/2014; Pedigree: W003679, EXP: 6/25/2014; Pedigree: AD60272_16, EXP: 5/22/2014; Pedigree: AD30140_10, EXP: 5/7/2014; Pedigree: W003000, EXP: 6/11/2014; Pedigree: W003326, EXP: 6/19/2014.

Recall Number: D-949-2014

Reason for Recall
Labeling: Label Mixup: ISONIAZID, Tablet, 300 mg may have potentially been mislabeled as one of the following drugs: hydrOXYzine PAMOATE, Capsule, 100 mg, NDC 00555032402, Pedigree: W003690, EXP: 6/26/2014; CETIRIZINE HCL, Tablet, 5 mg, NDC 00378363501, Pedigree: AD32757_13, EXP: 5/13/2014; RANOLAZINE ER, Tablet, 500 mg, NDC 61958100301, Pedigree: AD32757_47, EXP: 5/13/2014; DULoxetine HCl DR,
Initiated
07-02-2013
Reported
01-29-2014
Quantity
600 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ISONIAZID, Tablet, 300 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00555007102.

Batch or Lot Expiration Information

Lot# ISONIAZID, Tablet, 300 mg has the following codes: Pedigree: W003691, EXP: 6/26/2014; Pedigree: AD32757_31, EXP: 5/13/2014; Pedigree: AD32757_28, EXP: 5/13/2014; Pedigree: AD60272_70, EXP: 5/22/2014.

Recall Number: D-1005-2014

Reason for Recall
Labeling: Label Mixup: MYCOPHENOLATE MOFETIL, Capsule, 250 mg may have potentially been mislabeled as one of the following drugs: ATORVASTATIN CALCIUM, Tablet, 80 mg, NDC 00378212277, Pedigree: W003213, EXP: 6/14/2014; PROPRANOLOL HCL, Tablet, 10 mg, NDC 23155011010, Pedigree: AD65317_1, EXP: 5/24/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MYCOPHENOLATE MOFETIL, Capsule, 250 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781206701.

Batch or Lot Expiration Information

Lot# MYCOPHENOLATE MOFETIL, Capsule, 250 mg has the following codes: Pedigree: W003215, EXP: 6/14/2014; Pedigree: AD65457_7, EXP: 5/24/2014.

Recall Number: D-846-2014

Reason for Recall
Labeling: Label Mixup: VENLAFAXINE HCL, Tablet, 75 mg may have potentially been mislabeled as the following drug: TACROLIMUS, Capsule, 1 mg, NDC 00781210301, Pedigree: W002508, EXP: 6/3/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VENLAFAXINE HCL, Tablet, 75 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093738201.

Batch or Lot Expiration Information

Lot# VENLAFAXINE HCL, Tablet, 75 mg has the following codes: Pedigree: W002533, EXP: 2/28/2014.

Recall Number: D-1012-2014

Reason for Recall
Labeling: Label Mixup: LOSARTAN POTASSIUM, Tablet, 50 mg may have potentially been mislabeled as the following drug: ATORVASTATIN CALCIUM, Tablet, 80 mg, NDC 60505267109, Pedigree: AD21965_4, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LOSARTAN POTASSIUM, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781570192.

Batch or Lot Expiration Information

Lot# LOSARTAN POTASSIUM, Tablet, 50 mg has the following codes: Pedigree: AD21965_10, EXP: 5/1/2014.

Recall Number: D-1001-2014

Reason for Recall
Labeling: Label Mixup: ISOSORBIDE DINITRATE, Tablet, 5 mg may have potentially been mislabeled as one of the following drugs: CILOSTAZOL, Tablet, 100 mg, NDC 00054004421, Pedigree: W003470, EXP: 6/20/2014; PERPHENAZINE, Tablet, 8 mg, NDC 00630506221, Pedigree: AD54605_1, EXP: 4/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ISOSORBIDE DINITRATE, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781163501.

Batch or Lot Expiration Information

Lot# ISOSORBIDE DINITRATE, Tablet, 5 mg has the following codes: Pedigree: W003474, EXP: 6/20/2014; Pedigree: AD56882_1, EXP: 5/21/2014.

Recall Number: D-937-2014

Reason for Recall
Labeling: Label Mixup: CHOLECALCIFEROL, Capsule, 2000 units may have potentially been mislabeled as one of the following drugs: DOXYCYCLINE HYCLATE, Tablet, 100 mg, NDC 53489012002, Pedigree: AD30993_8, EXP: 5/9/2014; VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 50 mg, NDC 40985022251, Pedigree: AD60211_20, EXP: 5/21/2014; lamoTRIgine, Tablet, 50 mg (1/2 of 100 mg), NDC 13668004701, Pedigree: A
Initiated
07-02-2013
Reported
01-29-2014
Quantity
18,282 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CHOLECALCIFEROL, Capsule, 2000 units, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536379001.

Batch or Lot Expiration Information

Lot# CHOLECALCIFEROL, Capsule, 2000 units has the following codes: Pedigree: AD30028_7, EXP: 5/8/2014; Pedigree: AD60240_4, EXP: 5/22/2014; Pedigree: ADWA00002136, EXP: 5/31/2014; Pedigree: W002666, EXP: 6/5/2014; Pedigree: W003016, EXP: 6/12/2014; Pedigree: W003017, EXP: 6/12/2014; Pedigree: W003712, EXP: 6/26/2014; Pedigree: W003713, EXP: 6/26/2014; Pedigree: W003828, EXP: 6/27/2014; Pedigree: AD21846_4, EXP: 5/1/2014; Pedigree: AD46257_7, EXP: 5/15/2014; Pedigree: AD73521_7, EXP: 5/30/2014; Pedigree: W002691, EXP: 6/5/2014; Pedigree: W003314, EXP: 6/18/2014.

Recall Number: D-777-2014

Reason for Recall
Labeling: Label Mixup: CARVEDILOL PHOSPHATE ER, Capsule, 20 mg may be potentially mislabeled as the following drug: BUMETANIDE, Tablet, 1 mg, NDC 00093423301, Pedigree: W003224, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
29 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CARVEDILOL PHOSPHATE ER, Capsule, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00007337113.

Batch or Lot Expiration Information

Lot# CARVEDILOL PHOSPHATE ER, Capsule, 20 mg has the following codes: Pedigree: W003225, EXP: 6/17/2014.

Recall Number: D-1022-2014

Reason for Recall
Labeling: Label Mixup: THIAMINE HCL, Tablet, 100 mg may have potentially been mislabeled as one of the following drugs: SIMVASTATIN, Tablet, 5 mg, NDC 00093715298, Pedigree: AD65323_13, EXP: 5/29/2014; CALCIUM CARBONATE +D3, Tablet, 600 mg/400 units, NDC 00904323392, Pedigree: AD54576_1, EXP: 5/20/2014; BUPRENORPHINE HCL SL, Tablet, 2 mg, NDC 00054017613, Pedigree: AD54478_1, EXP: 5/20/2014; P
Initiated
07-02-2013
Reported
01-29-2014
Quantity
500 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
THIAMINE HCL, Tablet, 100 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904054460.

Batch or Lot Expiration Information

Lot# THIAMINE HCL, Tablet, 100 mg has the following codes: Pedigree: AD70639_1, EXP: 5/29/2014; Pedigree: AD54559_1, EXP: 5/20/2014; Pedigree: AD52993_16, EXP: 5/20/2014; Pedigree: W003408, EXP: 6/19/2014.

Recall Number: D-831-2014

Reason for Recall
Labeling: Label Mixup: NEFAZODONE HCL, Tablet, 200 mg may have potentially been mislabeled as the following drug: NEFAZODONE HCL, Tablet, 150 mg, NDC 00093711306, Pedigree: AD46414_41, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NEFAZODONE HCL, Tablet, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093102506.

Batch or Lot Expiration Information

Lot# NEFAZODONE HCL, Tablet, 200 mg has the following codes: Pedigree: AD46414_44, EXP: 5/16/2014

Recall Number: D-824-2014

Reason for Recall
Labeling: Label Mixup: DILTIAZEM HCL, Tablet, 120 mg, may have potentially been mislabeled as the following drug: NICOTINE POLACRILEX, LOZENGE, 2 mg, NDC 00135051001, Pedigree: AD329737, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DILTIAZEM HCL, Tablet, 120 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093032101.

Batch or Lot Expiration Information

Lot# DILTIAZEM HCL, Tablet, 120 mg, has the following codes: Pedigree: AD30197_1, EXP: 5/9/2014.

Recall Number: D-821-2014

Reason for Recall
Labeling: Label Mixup: DESLORATADINE, Tablet, 5 mg may have potentially been mislabeled as the following drug: ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: AD30180_28, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
101 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DESLORATADINE, Tablet, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00085126401.

Batch or Lot Expiration Information

Lot# DESLORATADINE, Tablet, 5 mg has the following codes: Pedigree: AD30993_5, EXP: 2/28/2014.

Recall Number: D-929-2014

Reason for Recall
Labeling: Label Mixup: CALCIUM/ CHOLECALCIFEROL/ SODIUM, Tablet, 600 mg/400 units/5 mg may have potentially been mislabeled as one of the following drugs: CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: W003460, EXP: 6/20/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 40985022921, Pedigree: AD60240_1, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
720 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CALCIUM/ CHOLECALCIFEROL/ SODIUM, Tablet, 600 mg/400 units/5 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536342408.

Batch or Lot Expiration Information

Lot# CALCIUM/ CHOLECALCIFEROL/ SODIUM, Tablet, 600 mg/400 units/5 mg has the following codes: Pedigree: W003461, EXP: 6/20/2014; Pedigree: AD60428_1, EXP: 5/22/2014.

Recall Number: D-966-2014

Reason for Recall
Labeling: Label Mixup: PROPAFENONE HCL, Tablet, 150 mg may have potentially been mislabeled as the following drug: FOSINOPRIL SODIUM, Tablet, 10 mg, NDC 00185004109, Pedigree: AD54549_7, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PROPAFENONE HCL, Tablet, 150 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591058201.

Batch or Lot Expiration Information

Lot# PROPAFENONE HCL, Tablet, 150 mg has the following codes: Pedigree: AD54549_13, EXP: 5/20/2014.

Recall Number: D-962-2014

Reason for Recall
Labeling: Label Mixup: VERAPAMIL HCL, Tablet, 40 mg may have potentially been mislabeled as one of the following drugs: ATORVASTATIN CALCIUM, Tablet, 10 mg, NDC 00378201577, Pedigree: W003095, EXP: 6/12/2014; TACROLIMUS, Capsule, 1 mg, NDC 00781210301, Pedigree: W003352, EXP: 3/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
196 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VERAPAMIL HCL, Tablet, 40 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591040401.

Batch or Lot Expiration Information

Lot# VERAPAMIL HCL, Tablet, 40 mg has the following codes: Pedigree: W003170, EXP: 6/13/2014; Pedigree: W003353, EXP: 6/18/2014.

Recall Number: D-888-2014

Reason for Recall
Labeling: Label Mixup: METOPROLOL TARTRATE, Tablet, 25 mg may have potentially been mislabeled as the following drug: DOCUSATE SODIUM, Capsule, 250 mg, NDC 00536375710, Pedigree: AD76675_1, EXP: 6/3/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
METOPROLOL TARTRATE, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378001801.

Batch or Lot Expiration Information

Lot# METOPROLOL TARTRATE, Tablet, 25 mg has the following codes: Pedigree: W002535, EXP: 6/3/2014.

Recall Number: D-1016-2014

Reason for Recall
Labeling: Label Mixup: VITAMIN B COMPLEX W/C, Tablet, 0 mg may have potentially been mislabeled as one of the following drugs: MULTIVITAMIN/ MULTIMINERAL/ LUTEIN, Capsule, 0 mg, NDC 24208063210, Pedigree: AD21846_40, EXP: 5/2/2014; CALCIUM CARBONATE/CHOLECALCIFEROL, Tablet, 600 mg/800 units, NDC 00005550924, Pedigree: AD52993_1, EXP: 5/17/2014; MULTIVITAMIN/ MULTIMINERAL/ LUTEIN, Capsule, 0, ND
Initiated
07-02-2013
Reported
01-29-2014
Quantity
780 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VITAMIN B COMPLEX W/C, Tablet, 0 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904026013.

Batch or Lot Expiration Information

Lot# VITAMIN B COMPLEX W/C, Tablet, 0 mg has the following codes: Pedigree: AD21846_43, EXP: 5/1/2014; Pedigree: AD52993_31, EXP: 5/17/2014; Pedigree: AD60240_48, EXP: 5/22/2014; Pedigree: W003321, EXP: 6/19/2014; Pedigree: AD46419_7, EXP: 5/16/2014.

Recall Number: D-970-2014

Reason for Recall
Labeling: Label Mixup: NIFEdipine ER, Tablet, 60 mg may have potentially been mislabeled as the following drug: NICOTINE POLACRILEX, LOZENGE, 2 mg, NDC 00135051001, Pedigree: W003749, EXP: 6/26/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIFEdipine ER, Tablet, 60 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591319401.

Batch or Lot Expiration Information

Lot# NIFEdipine ER, Tablet, 60 mg has the following codes: Pedigree: W003729, EXP: 6/26/2014.

Recall Number: D-890-2014

Reason for Recall
Labeling: Label Mixup: CHLORTHALIDONE, Tablet, 12.5 mg (1/2 of 25 mg) may have potentially been mislabeled as the following drug: PROPRANOLOL HCL, Tablet, 5 mg (1/2 of 10 mg), NDC 23155011001, Pedigree: AD73525_25, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CHLORTHALIDONE, Tablet, 12.5 mg (1/2 of 25 mg), Rx only, Distributed by: AidaPak Service, LLC, NDC 00378022201.

Batch or Lot Expiration Information

Lot# CHLORTHALIDONE, Tablet, 12.5 mg (1/2 of 25 mg) has the following codes: Pedigree: AD73525_43, EXP: 5/30/2014.

Recall Number: D-973-2014

Reason for Recall
Labeling: Label Mixup:PROGESTERONE, Capsule, 100 mg may have potentially been mislabeled as the following drug: ASCORBIC ACID, Tablet, 250 mg, NDC 00904052260, Pedigree: AD73623_10, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
99 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PROGESTERONE, Capsule, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591396401.

Batch or Lot Expiration Information

Lot# PROGESTERONE, Capsule, 100 mg has the following codes: Pedigree: AD73611_4, EXP: 5/30/2014.

Recall Number: D-983-2014

Reason for Recall
Labeling: Label Mixup: GLYCOPYRROLATE, Tablet, 2 mg may have potentially been mislabeled as one of the following drugs: PARICALCITOL, Capsule, 1 mcg, NDC 00074431730, Pedigree: W002667, EXP: 6/5/2014; guaiFENesin ER, Tablet, 600 mg, NDC 63824000850, Pedigree: W003244, EXP: 6/17/2014; LACTOBACILLUS, Tablet, 0, NDC 64980012950, Pedigree: AD22865_1, EXP: 5/2/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1300 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
GLYCOPYRROLATE, Tablet, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603318121.

Batch or Lot Expiration Information

Lot# GLYCOPYRROLATE, Tablet, 2 mg has the following codes: Pedigree: W002650, 6/5/2014; Pedigree: W003252, 6/17/2014; Pedigree: AD22865_4, 5/2/2014.

Recall Number: D-862-2014

Reason for Recall
Labeling: Label Mixup: NICOTINE POLACRILEX, LOZENGE, 2 mg may have potentially been mislabeled as one of the following drugs: ESTRADIOL, Tablet, 0.5 mg, NDC 00555089902, Pedigree: AD30993_11, EXP: 5/9/2014; ACAMPROSATE CALCIUM DR, Tablet, 333 mg, NDC 00456333001, Pedigree: W002973, EXP: 6/11/2014; CALCITRIOL, Capsule, 0.5 mcg, NDC 63304024001, Pedigree: W003730, EXP: 6/26/2014; ESZOPICLONE, T
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1216 Lozenges

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NICOTINE POLACRILEX, LOZENGE, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00135051001.

Batch or Lot Expiration Information

Lot# NICOTINE POLACRILEX, LOZENGE, 2 mg has the following codes: Pedigree: AD32973_7, EXP: 5/9/2014; Pedigree: W002974, EXP: 6/11/2014; Pedigree: W003749, EXP: 6/26/2014; Pedigree: W002766, EXP: 6/6/2014; Pedigree: AD21858_1, EXP: 5/1/2014; Pedigree: AD46333_10, EXP: 5/16/2014.

Recall Number: D-857-2014

Reason for Recall
Labeling: Label Mixup: ACYCLOVIR, Capsule, 200 mg may have potentially been mislabeled as one of the following drugs: CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00904421713, Pedigree: AD60240_51, EXP: 5/22/2014; METOPROLOL TARTRATE, Tablet, 25 mg, NDC 57664050652, Pedigree: W002841, EXP: 6/7/2014; METOPROLOL TARTRATE, Tablet, 50 mg, NDC 00093073301, Pedigree: W003900, EXP: 6/27/2014; acetaZOLAMIDE
Initiated
07-02-2013
Reported
01-29-2014
Quantity
493 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ACYCLOVIR, Capsule, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093894001.

Batch or Lot Expiration Information

Lot# ACYCLOVIR, Capsule, 200 mg has the following codes: Pedigree: AD60272_4, EXP: 5/22/2014; Pedigree: W002899, EXP: 6/10/2014; Pedigree: W003911, EXP: 6/27/2014; Pedigree: W003483, EXP: 6/20/2014.

Recall Number: D-1007-2014

Reason for Recall
Labeling: Label Mixup: TACROLIMUS, Capsule, 1 mg may have potentially been mislabeled as one of the following drugs: BISOPROLOL FUMARATE, Tablet, 5 mg, NDC 29300012601, Pedigree: AD34934_7, EXP: 5/10/2014; SEVELAMER CARBONATE, Tablet, 800 mg, NDC 58468013001, Pedigree: AD56917_4, EXP: 5/21/2014; SEVELAMER CARBONATE, Tablet, 800 mg, NDC 58468013001, Pedigree: AD73627_11, EXP: 5/30/2014; ATOMOXE
Initiated
07-02-2013
Reported
01-29-2014
Quantity
700 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TACROLIMUS, Capsule, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781210301.

Batch or Lot Expiration Information

Lot# TACROLIMUS, Capsule, 1 mg has the following codes: Pedigree: AD37056_1, EXP: 5/10/2014; Pedigree: AD56917_7, EXP: 5/21/2014; Pedigree: AD73627_14, EXP: 5/30/2014; Pedigree: W003704, EXP: 6/26/2014; Pedigree: W002508, EXP: 6/3/2014; Pedigree: W003049, EXP: 6/12/2014; Pedigree: W003352, EXP: 3/31/2014.

Recall Number: D-977-2014

Reason for Recall
Labeling: Label Mixup:MINOXIDIL, Tablet, 2.5 mg may have potentially been mislabeled as the following drug: methylPREDNISolone, Tablet, 4 mg, NDC 00781502201, Pedigree: AD52778_43, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MINOXIDIL, Tablet, 2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591564201.

Batch or Lot Expiration Information

Lot# MINOXIDIL, Tablet, 2.5 mg has the following codes: Pedigree: AD52778_49, EXP: 5/20/2014.

Recall Number: D-979-2014

Reason for Recall
Labeling: Label Mixup: MINOCYCLINE HCL, Capsule, 100 mg may have potentially been mislabeled as the following drug: PROGESTERONE, Capsule, 100 mg, NDC 00591396401, Pedigree: AD73611_4, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
50 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MINOCYCLINE HCL, Capsule, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591569550.

Batch or Lot Expiration Information

Lot# MINOCYCLINE HCL, Capsule, 100 mg has the following codes: Pedigree: AD73611_10, EXP: 5/30/2014.

Recall Number: D-807-2014

Reason for Recall
Labeling: Label Mixup: PHENYTOIN SODIUM ER, Capsule, 30 mg may have potentially been mislabeled as the following drug: LITHIUM CARBONATE ER, Tablet, 450 mg, NDC 00054002025, Pedigree: W003327, EXP: 6/19/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PHENYTOIN SODIUM ER, Capsule, 30 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00071374066.

Batch or Lot Expiration Information

Lot# PHENYTOIN SODIUM ER, Capsule, 30 mg has the following codes: Pedigree: W003331, EXP: 6/19/2014.

Recall Number: D-799-2014

Reason for Recall
Labeling: Label Mixup: MERCapsuleTOPURINE, Tablet, 50 mg may have potentially been mislabeled as the following drug: ASCORBIC ACID, Tablet, 500 mg, NDC 00904052380, Pedigree: AD54576_4, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
25 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MERCapsuleTOPURINE, Tablet, 50 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054458111.

Batch or Lot Expiration Information

Lot# MERCapsuleTOPURINE, Tablet, 50 mg has the following codes: Pedigree: AD54549_1, EXP: 5/20/2014.

Recall Number: D-1018-2014

Reason for Recall
Labeling: Label Mixup: ASCORBIC ACID, Tablet, 250 mg may have potentially been mislabeled as one of the following drugs: PREGABALIN, Capsule, 200 mg, NDC 00071101768, Pedigree: AD30024_1, EXP: 5/9/2014; NIFEDIPINE, Capsule, 10 mg, NDC 43386044024, Pedigree: AD23082_10, EXP: 9/23/2013; PIMOZIDE, Tablet, 2 mg, NDC 57844018701, Pedigree: AD30140_43, EXP: 5/7/2014; OMEGA-3-ACID ETHYL ESTERS, Capsu
Initiated
07-02-2013
Reported
01-29-2014
Quantity
3301 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASCORBIC ACID, Tablet, 250 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904052260.

Batch or Lot Expiration Information

Lot# ASCORBIC ACID, Tablet, 250 mg may have potentially been mislabeled as one of the following drugs: PREGABALIN, Capsule, 200 mg, NDC 00071101768, Pedigree: AD30024_1, EXP: 5/9/2014; NIFEDIPINE, Capsule, 10 mg, NDC 43386044024, Pedigree: AD23082_10, EXP: 9/23/2013; PIMOZIDE, Tablet, 2 mg, NDC 57844018701, Pedigree: AD30140_43, EXP: 5/7/2014; OMEGA-3-ACID ETHYL ESTERS, Capsule, 1000 mg, NDC 00173078302, Pedigree: AD46265_43, EXP: 5/15/2014; PRENATAL MULTIVITAMIN/MULTIMINERAL, Tablet, 0, NDC 00904531360, Pedigree: W003098, EXP: 6/13/2014; PYRIDOXINE HCL, Tablet, 50 mg, NDC 51645090901, Pedigree: W003718, EXP: 6/26/2014; QUEtiapine FUMARATE, Tablet, 100 mg, NDC 60505313301, Pedigree: W003825, EXP: 6/27/2014; BISMUTH SUBSALICYLATE, CHEW Tablet, 262 mg, NDC 00603023516, Pedigree: AD42592_10, EXP: 5/14/2014; OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 00904404360, Pedigree: AD73623_4, EXP: 5/30/2014; LACTOBACILLUS ACIDOPHILUS, Capsule, 500 MILLION CFU, NDC 43292055746, Pedigree: W002698, EXP: 6/5/2014; traZODone HCl, Tablet, 150 mg, NDC 50111044101, Pedigree: AD21858_7, EXP: 5/1/2014; CHOLECALCIFEROL, Tablet, 400 units, NDC 00904582360, Pedigree: AD30197_31, EXP: 5/9/2014; CYANOCOBALAMIN, Tablet, 1000 mcg, NDC 00904421713, Pedigree: W003026, EXP: 6/12/2014.

Recall Number: D-944-2014

Reason for Recall
Labeling: Label Mixup: NIACIN TR, Tablet, 750 mg may have potentially been mislabeled as the following drug: NORTRIPTYLINE HCL, Capsule, 50 mg, NDC 00093081201, Pedigree: AD46414_47, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIACIN TR, Tablet, 750 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00536703301.

Batch or Lot Expiration Information

Lot# NIACIN TR, Tablet, 750 mg has the following codes: Pedigree: AD46414_56, EXP: 5/16/2014.

Recall Number: D-905-2014

Reason for Recall
Labeling: Label Mixup: TEMAZEPAM, Capsule, 7.5 mg may have potentially been mislabeled as one of the following drugs: CALCIUM CITRATE, Tablet, 200 mg Elemental Calcium, NDC 00904506260, Pedigree: AD28333_1, EXP: 5/8/2014; VALSARTAN, Tablet, 160 mg, NDC 00078035934, Pedigree: AD49414_7, EXP: 5/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TEMAZEPAM, Capsule, 7.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378311001.

Batch or Lot Expiration Information

Lot# TEMAZEPAM, Capsule, 7.5 mg has the following codes: Pedigree: AD22861_7, EXP: 5/8/2014; Pedigree: AD49418_1, EXP: 5/17/2014.

Recall Number: D-976-2014

Reason for Recall
Labeling: Label Mixup:predniSONE, Tablet, 20 mg may have potentially been mislabeled as the following drug: methylPREDNISolone, Tablet, 4 mg, NDC 00781502201, Pedigree: AD54587_7, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
603 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
predniSONE, Tablet, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591544301.

Batch or Lot Expiration Information

Lot# predniSONE, Tablet, 20 mg has the following codes: Pedigree: AD56879_5, EXP: 5/21/2014.

Recall Number: D-838-2014

Reason for Recall
Labeling: Label Mixup: BUMETANIDE, Tablet, 1 mg may have potentially been mislabeled as the following drug: guaiFENesin ER, Tablet, 600 mg, NDC 63824000815, Pedigree: W003218, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
BUMETANIDE, Tablet, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093423301.

Batch or Lot Expiration Information

Lot# BUMETANIDE, Tablet, 1 mg has the following codes: Pedigree: W003224, EXP: 6/17/2014.

Recall Number: D-1000-2014

Reason for Recall
Labeling: Label Mixup: ISOSORBIDE DINITRATE, Tablet, 10 mg may have potentially been mislabeled as one of the following drugs: SODIUM CHLORIDE, Tablet, 1 mg, NDC 00223176001, Pedigree: AD22845_10, EXP: 5/2/2014; CALCITRIOL, Capsule, 0.5 mcg, NDC 63304024001, Pedigree: AD32757_10, EXP: 5/14/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
384 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ISOSORBIDE DINITRATE, Tablet, 10 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781155601.

Batch or Lot Expiration Information

Lot# ISOSORBIDE DINITRATE, Tablet, 10 mg has the following codes: Pedigree: AD25264_1, EXP: 5/3/2014; Pedigree: AD32757_34, EXP: 5/14/2014.

Recall Number: D-884-2014

Reason for Recall
Labeling: Label Mixup: GABAPENTIN, Tablet, 600 mg may have potentially been mislabeled as the following drug: ARIPiprazole, Tablet, 15 mg, NDC 59148000913, Pedigree: AD21965_1, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
GABAPENTIN, Tablet, 600 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00228263611.

Batch or Lot Expiration Information

Lot# GABAPENTIN, Tablet, 600 mg has the following codes: Pedigree: AD21965_7, EXP: 5/1/2014.

Recall Number: D-1009-2014

Reason for Recall
Labeling: Label Mixup: LEVOTHYROXINE SODIUM, Tablet, 88 mcg may have potentially been mislabeled as one of the following drugs: clomiPRAMINE HCl, Capsule, 50 mg, NDC 51672401205, Pedigree: AD46265_1, EXP: 5/15/2014; HYDROXYCHLOROQUINE SULFATE, Tablet, 200 mg, NDC 63304029601, Pedigree: AD70629_10, EXP: 5/29/2014; HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, NDC 76439030910, Pedigree: W003438, EXP:
Initiated
07-02-2013
Reported
01-29-2014
Quantity
360 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LEVOTHYROXINE SODIUM, Tablet, 88 mcg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781518392.

Batch or Lot Expiration Information

Lot# LEVOTHYROXINE SODIUM, Tablet, 88 mcg has the following codes: Pedigree: AD46265_34, EXP: 5/15/2014; Pedigree: AD70629_13, EXP: 5/29/2014; Pedigree: W003439, EXP: 6/20/2014; Pedigree: AD60272_73, EXP: 5/22/2014.

Recall Number: D-912-2014

Reason for Recall
Labeling: Label Mixup: MESALAMINE DR, Capsule, 400 mg may have potentially been mislabeled as the following drug: CHLOROPHYLLIN COPPER COMPLEX, Tablet, 100 mg, NDC 11868000901, Pedigree: AD34928_1, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
180 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MESALAMINE DR, Capsule, 400 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00430075327.

Batch or Lot Expiration Information

Lot# MESALAMINE DR, Capsule, 400 mg has the following codes: Pedigree: AD34934_1, EXP: 1/31/2014.

Recall Number: D-968-2014

Reason for Recall
Labeling: Label Mixup: DESMOPRESSIN ACETATE, Tablet 0.1 mg may have potentially been mislabeled as the following drug: LOXAPINE, Capsule, 5 mg, NDC 00591036901, Pedigree: AD46426_7, EXP: 5/15/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
98 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DESMOPRESSIN ACETATE, Tablet 0.1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591246401.

Batch or Lot Expiration Information

Lot# DESMOPRESSIN ACETATE, Tablet 0.1 mg has the following codes: Pedigree: AD46426_16, EXP: 5/15/2014.

Recall Number: D-800-2014

Reason for Recall
Labeling: Label Mixup: EFAVIRENZ, Capsule, 200 mg may have potentially been mislabeled as the following drug: metFORMIN HCl, Tablet 500 mg, NDC 23155010201, Pedigree: AD46312_25, EXP: 5/16/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
EFAVIRENZ, Capsule, 200 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00056047492.

Batch or Lot Expiration Information

Lot# EFAVIRENZ , Capsule, 200 mg has the following codes: Pedigree: AD46312_31, EXP: 5/16/2014.

Recall Number: D-878-2014

Reason for Recall
Labeling: Label Mixup: FOSINOPRIL SODIUM, Tablet, 10 mg may have potentially been mislabeled as the following drug: MERCapsuleTOPURINE, Tablet, 50 mg, NDC 00054458111, Pedigree: AD54549_1, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FOSINOPRIL SODIUM, Tablet, 10 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00185004109.

Batch or Lot Expiration Information

Lot# FOSINOPRIL SODIUM, Tablet, 10 mg has the following codes: Pedigree: AD54549_7, EXP: 5/20/2014.

Recall Number: D-860-2014

Reason for Recall
Labeling: Label Mixup: FENOFIBRATE, Tablet, 54 mg may have potentially been mislabeled as the following drug: FAMCICLOVIR, Tablet, 500 mg, NDC 00093811956, Pedigree: AD49448_4, EXP: 5/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FENOFIBRATE, Tablet, 54 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00115551110.

Batch or Lot Expiration Information

Lot# FENOFIBRATE, Tablet, 54 mg has the following codes: Pedigree: AD49448_7, EXP: 5/17/2014.

Recall Number: D-803-2014

Reason for Recall
Labeling: Label Mixup: VARENICLINE, Tablet, 0.5 mg may have potentially been mislabeled as one of the following drugs: LACTOBACILLUS GG, Capsule, 0, NDC 49100036374, Pedigree: W003051, EXP: 6/12/2014; SOTALOL HCL, Tablet, 160 mg, NDC 00093106201, Pedigree: AD22609_10, EXP: 4/30/2014; VENLAFAXINE HCL, Tablet, 25 mg, NDC 00093019901, Pedigree: AD62796_4, EXP: 5/22/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
168 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VARENICLINE, Tablet, 0.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00069046856.

Batch or Lot Expiration Information

Lot# VARENICLINE, Tablet, 0.5 mg has the following codes: Pedigree: W003083, EXP: 6/12/2014; Pedigree: AD22616_1, EXP: 5/2/2014; Pedigree: AD62829_1, EXP: 5/22/2014.

Recall Number: D-961-2014

Reason for Recall
Labeling: Label Mixup: LOXAPINE, Capsule, 5 mg may have potentially been mislabeled as the following drug: SERTRALINE HCL, Tablet, 50 mg, NDC 16714061204, Pedigree: AD46426_1, EXP: 5/15/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LOXAPINE, Capsule, 5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591036901.

Batch or Lot Expiration Information

Lot# LOXAPINE, Capsule, 5 mg has the following codes: Pedigree: AD46426_7, EXP: 5/15/2014.

Recall Number: D-780-2014

Reason for Recall
Labeling: Label Mixup: TOLTERODINE TARTRATE ER, Capsule, 2 mg may be potentially mislabeled as one of the following drugs: RANOLAZINE ER , Tablet, 500 mg, NDC 61958100301, Pedigree: AD62995_7, EXP: 5/29/2014; FERROUS SULFATE, Tablet, 325 mg (65 mg Elem Fe), NDC 00904759160, Pedigree: W002717, EXP: 6/6/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TOLTERODINE TARTRATE ER, Capsule, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00009519001.

Batch or Lot Expiration Information

Lot# TOLTERODINE TARTRATE ER, Capsule, 2 mg has the following codes: Pedigree: AD65478_1, EXP: 5/29/2014; Pedigree: W002724, EXP: 6/6/2014.

Recall Number: D-778-2014

Reason for Recall
Labeling: Label Mixup: PANTOPRAZOLE SODIUM DR, Tablet, 20 mg may be potentially mislabeled as one of the following drugs: HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, NDC 00574025001, Pedigree: AD60272_16, EXP: 5/22/2014; MULTIVITAMIN/MULTIMINERAL, Tablet, 0 mg, NDC 65162066810, Pedigree: AD73646_13, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
180 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PANTOPRAZOLE SODIUM DR, Tablet, 20 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00008060601.

Batch or Lot Expiration Information

Lot# PANTOPRAZOLE SODIUM DR, Tablet, 20 mg has the following codes: Pedigree: AD60272_28, EXP: 5/22/2014; Pedigree: AD73525_19, EXP: 5/30/2014

Recall Number: D-990-2014

Reason for Recall
Labeling: Label Mixup: PHENobarbital, Tablet, 64.8 mg may have potentially been mislabeled as the following drug: PREGABALIN, Capsule, 200 mg, NDC 00071101768, Pedigree: AD73518_4, EXP: 5/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PHENobarbital, Tablet, 64.8 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00603516721.

Batch or Lot Expiration Information

Lot# PHENobarbital, Tablet, 64.8 mg has the following codes: Pedigree: AD73518_7, EXP: 5/31/2014.

Recall Number: D-1003-2014

Reason for Recall
Labeling: Label Mixup: AMANTADINE HCL, Capsule, 100 mg may have potentially been mislabeled as one of the following drugs: ACARBOSE, Tablet, 25 mg, NDC 00054014025, Pedigree: W002725, EXP: 6/6/2014; clomiPRAMINE HCl, Capsule, 50 mg, NDC 51672401205, Pedigree: W002998, EXP: 6/11/2014; ASPIRIN EC DR, Tablet, 81 mg, NDC 49348098015, Pedigree: W003672, EXP: 2/28/2014; NIACIN TR, Capsule, 500 mg, N
Initiated
07-02-2013
Reported
01-29-2014
Quantity
499 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
AMANTADINE HCL, Capsule, 100 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00781204801.

Batch or Lot Expiration Information

Lot# AMANTADINE HCL, Capsule, 100 mg has the following codes: Pedigree: W002726, EXP: 6/6/2014; Pedigree: W002997, EXP: 6/11/2014; Pedigree: W003674, EXP: 6/25/2014; Pedigree: W003323, EXP: 6/18/2014.

Recall Number: D-916-2014

Reason for Recall
Labeling: Label Mixup: POTASSIUM ACID PHOSPHATE, Tablet, 500 mg may have potentially been mislabeled as the following drug: predniSONE, Tablet, 20 mg, NDC 00591544301, Pedigree: AD56879_5, EXP: 5/21/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
POTASSIUM ACID PHOSPHATE, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00486111101.

Batch or Lot Expiration Information

Lot# POTASSIUM ACID PHOSPHATE, Tablet, 500 mg has the following codes: Pedigree: AD52778_34, EXP: 5/20/2014.

Recall Number: D-876-2014

Reason for Recall
Labeling: Label Mixup: SENNOSIDES, Tablet, 8.6 mg may have potentially been mislabeled as one of the following drugs: FEXOFENADINE HCL, Tablet, 180 mg, NDC 41167412003, Pedigree: AD62834_1, EXP: 5/23/2014; TRIMETHOBENZAMIDE HCL, Capsule, 300 mg, NDC 53489037601, Pedigree: W002976, EXP: 6/11/2014; LORATADINE, Tablet, 10 mg, NDC 45802065078, Pedigree: W003253, EXP: 6/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
1400 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SENNOSIDES, Tablet, 8.6 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00182109301.

Batch or Lot Expiration Information

Lot# SENNOSIDES, Tablet, 8.6 mg has the following codes: Pedigree: AD62992_14, EXP: 5/23/2014; Pedigree: W002979, EXP: 6/11/2014; Pedigree: W003256, EXP: 6/17/2014.

Recall Number: D-779-2014

Reason for Recall
Labeling: Label Mixup: SIROLIMUS, Tablet, 1 mg may be potentially mislabeled as one of the following drugs: PROPRANOLOL HCL, Tablet, 10 mg, NDC 23155011001, Pedigree: AD60272_34, EXP: 5/22/2014; HYDROCORTISONE, Tablet, 5 mg, NDC 00603389919, Pedigree: W003325, EXP: 6/18/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
200 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SIROLIMUS, Tablet, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00008104105.

Batch or Lot Expiration Information

Lot# SIROLIMUS, Tablet, 1 mg has the following product codes: Pedigree: AD60272_43, EXP: 5/22/2014; Pedigree: W003329, EXP: 6/18/2014.

Recall Number: D-1020-2014

Reason for Recall
Labeling: Label Mixup: ASCORBIC ACID, Tablet, 500 mg may have potentially been mislabeled as the following drug: OXcarbazepine, Tablet, 150 mg, NDC 62756018388, Pedigree: AD54562_4, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
2018 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ASCORBIC ACID, Tablet, 500 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00904052380.

Batch or Lot Expiration Information

Lot# ASCORBIC ACID, Tablet, 500 mg has the following codes: Pedigree: AD54576_4, EXP: 5/20/2014.

Recall Number: D-795-2014

Reason for Recall
Labeling: Label Mixup: ACARBOSE, Tablet, 25 mg may be potentially mislabeled as one of the following drugs: ZINC GLUCONATE, Tablet, 50 mg, NDC 00904319160, Pedigree: AD60240_57, EXP: 5/22/2014; TOLTERODINE TARTRATE ER, Capsule, 2 mg, NDC 00009519001, Pedigree: W002724, EXP: 6/6/2014; SILDENAFIL CITRATE, Tablet, 25 mg, NDC 00069420030, Pedigree: W003646, EXP: 6/25/2014; SEVELAMER CARBONATE, Tab
Initiated
07-02-2013
Reported
01-29-2014
Quantity
399 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ACARBOSE, Tablet, 25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054014025.

Batch or Lot Expiration Information

Lot# ACARBOSE, Tablet, 25 mg has the following codes: Pedigree: AD60272_1, EXP: 5/22/2014; Pedigree: W002725, EXP: 6/6/2014; Pedigree: W003673, EXP: 6/25/2014; Pedigree: W002996, EXP: 6/11/2014.

Recall Number: D-882-2014

Reason for Recall
Labeling: Label Mixup: CANDESARTAN CILEXETIL, Tablet, 16 mg may have potentially been mislabeled as the following drug: IRBESARTAN, Tablet, 150 mg, NDC 65862063830, Pedigree: W003649, EXP: 6/25/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CANDESARTAN CILEXETIL, Tablet, 16 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00186001631.

Batch or Lot Expiration Information

Lot# CANDESARTAN CILEXETIL, Tablet, 16 mg has the following codes: Pedigree: W003611, EXP: 6/25/2014.

Recall Number: D-832-2014

Reason for Recall
Labeling: Label Mixup: SOTALOL HCL, Tablet, 120 mg may have potentially been mislabeled as the following drug: NEOMYCIN SULFATE, Tablet, 500 mg, NDC 51991073801, Pedigree: AD49448_17, EXP: 5/17/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
101 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SOTALOL HCL, Tablet, 120 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093106001.

Batch or Lot Expiration Information

Lot# SOTALOL HCL, Tablet, 120 mg has the following codes: Pedigree: AD49448_20 EXP: 5/17/2014.

Recall Number: D-791-2014

Reason for Recall
Labeling: Label Mixup: LITHIUM CARBONATE ER, Tablet, 300 mg may be potentially mislabled as the following drug: VITAMIN B COMPLEX PROLONGED RELEASE, Tablet, 50 mg, NDC 40985022251, Pedigree: AD39588_10, EXP: 5/13/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
2400 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LITHIUM CARBONATE ER, Tablet, 300 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054002125.

Batch or Lot Expiration Information

Lot# LITHIUM CARBONATE ER, Tablet, 300 mg has the following codes: Pedigree: AD39564_1, EXP: 5/13/2014.

Recall Number: D-801-2014

Reason for Recall
Labeling: Label Mixup: EFAVIRENZ, Tablet, 600 mg may have potentially been mislabeled as the following drug: NIACIN ER, Tablet, 500 mg, NDC 00074307490, Pedigree: AD73637_1, EXP: 5/30/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
30 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
EFAVIRENZ, Tablet, 600 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00056051030.

Batch or Lot Expiration Information

Lot# EFAVIRENZ, Tablet, 600 mg has the following codes: Pedigree: AD73646_16, EXP: 5/30/2014.

Recall Number: D-953-2014

Reason for Recall
Labeling: Label Mixup: BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg may have potentially been mislabeled as the following drug: CAFFEINE, Tablet, 200 mg, NDC 24385060173, Pedigree: W003725, EXP: 6/26/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
102 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00574010601.

Batch or Lot Expiration Information

Lot# BROMOCRIPTINE MESYLATE, Tablet, 2.5 mg has the following codes: Pedigree: W003754, EXP: 6/26/2014.

Recall Number: D-796-2014

Reason for Recall
Labeling: Label Mixup: BUPRENORPHINE HCL SL, Tablet, 2 mg may be potentially mislabeled as one of the following drugs: DOCUSATE SODIUM, Capsule, 250 mg, NDC 00904789159, Pedigree: AD37072_4, EXP: 5/13/2014; MAGNESIUM CHLORIDE DR, Tablet, 64 mg, NDC 00904791152, Pedigree: AD54510_1, EXP: 2/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
BUPRENORPHINE HCL SL, Tablet, 2 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00054017613.

Batch or Lot Expiration Information

Lot# BUPRENORPHINE HCL SL, Tablet, 2 mg has the following codes: Pedigree: AD39573_1, EXP: 5/13/2014; Pedigree: AD54478_1, EXP: 5/20/2014.

Recall Number: D-851-2014

Reason for Recall
Labeling: Label Mixup: FAMCICLOVIR, Tablet, 500 mg may have potentially been mislabeled as one of the following drugs: TOLTERODINE TARTRATE ER, Capsule, 4 mg, NDC 00009519101, Pedigree: AD49448_1, EXP: 5/17/2014; THIAMINE HCL, Tablet, 100 mg, NDC 00904054460, Pedigree: AD54559_1, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
60 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
FAMCICLOVIR, Tablet, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093811956.

Batch or Lot Expiration Information

Lot# FAMCICLOVIR, Tablet, 500 mg has the following codes: Pedigree: AD49448_4, EXP 5/17/2014; Pedigree: AD54549_4, EXP: 5/20/2014.

Recall Number: D-963-2014

Reason for Recall
Labeling: Label Mixup: ESTROPIPATE, Tablet, 0.75 mg may have potentially been mislabeled as the following drug: MESALAMINE DR, Capsule, 400 mg, NDC 00430075327, Pedigree: AD34934_1, EXP: 1/31/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
ESTROPIPATE, Tablet, 0.75 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00591041401.

Batch or Lot Expiration Information

Lot# ESTROPIPATE, Tablet, 0.75 mg has the following codes: Pedigree: AD34934_4, EXP: 5/10/2014

Recall Number: D-819-2014

Reason for Recall
Labeling: Label Mixup: VALSARTAN, Tablet, 40 mg may have potentially been mislabeled as one of the following drugs: VALSARTAN, Tablet, 80 mg, NDC 00078035834, Pedigree: AD52372_4, EXP: 5/17/2014; ZINC SULFATE, Capsule, 50 mg, NDC 00904533260, Pedigree: AD30994_8, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
90 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
VALSARTAN, Tablet, 40 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00078042315.

Batch or Lot Expiration Information

Lot# VALSARTAN, Tablet, 40 mg has the following codes: Pedigree: AD52372_1, EXP: 5/17/2014; Pedigree: AD32579_1, EXP: 5/9/2014.

Recall Number: D-896-2014

Reason for Recall
Labeling: Label Mixup: TRIAMTERENE/HCTZ, Tablet, 37.5 mg/25 mg may have potentially been mislabeled as the following drug: CAFFEINE, Tablet, 100 mg (1/2 of 200 mg), NDC 24385060173, Pedigree: AD30028_31, EXP: 5/8/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
TRIAMTERENE/HCTZ, Tablet, 37.5 mg/25 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378135201.

Batch or Lot Expiration Information

Lot# TRIAMTERENE/HCTZ, Tablet, 37.5 mg/25 mghas the following codes: Pedigree: AD28333_4, EXP: 5/6/2014.

Recall Number: D-798-2014

Reason for Recall
Labeling: Label Mixup: DEXAMETHASONE, Tablet, 1 mg may have potentially been mislabeled as the following drug: VENLAFAXINE HCL ER, Capsule, 150 mg, NDC 00093738656, Pedigree: AD30993_20, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
DEXAMETHASONE, Tablet, 1 mg, Rx only, Distributed by Aidapack Service, LLC, NDC 00054418125.

Batch or Lot Expiration Information

Lot# DEXAMETHASONE, Tablet, 1 mg has the following codes: Pedigree: AD37088_1, EXP: 5/9/2014.

Recall Number: D-894-2014

Reason for Recall
Labeling: Label Mixup: THIOTHIXENE, Capsule, 1 mg may have potentially been mislabeled as the following drug: OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 40985022921, Pedigree: AD46257_1, EXP: 5/15/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
THIOTHIXENE, Capsule, 1 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00378100101.

Batch or Lot Expiration Information

Lot# THIOTHIXENE, Capsule, 1 mg has the following codes: Pedigree: AD54549_22, EXP: 5/20/2014.

Recall Number: D-940-2014

Reason for Recall
Labeling: Label Mixup: PYRIDOXINE HCL, Tablet, 25 mg may have potentially been mislabeled as the following drug: TORSEMIDE, Tablet, 10 mg, NDC 50111091601, Pedigree: AD30197_25, EXP: 5/9/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
102 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
PYRIDOXINE HCL, Tablet, 25 mg, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536440601.

Batch or Lot Expiration Information

Lot# PYRIDOXINE HCL, Tablet, 25 mg has the following codes: Pedigree: AD30197_28, EXP: 5/9/2014.

Recall Number: D-775-2014

Reason for Recall
Labeling: Label Mixup: RALTEGRAVIR, Tablet, 400 mg may be potentially mis-labeled as one of the following drugs: HYDROCORTISONE, Tablet, 5 mg, NDC00603389919, Pedigree: AD60272_13, EXP: 5/22/2014; HYOSCYAMINE SULFATE SL, Tablet, 0.125 mg, NDC 00574025001, Pedigree: W003679, EXP: 6/25/2014; HYDROCORTISONE, Tablet, 5 mg, NDC 00603389919, Pedigree: AD21790_16, EXP: 5/1/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
183 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
RALTEGRAVIR, Tablet, 400 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00006022761.

Batch or Lot Expiration Information

Lot# RALTEGRAVIR, Tablet, 400 mg has the following codes: Pedigree: AD60272_19, EXP: 5/22/2014; Pedigree: W003680, EXP: 6/25/2014; Pedigree: AD21790_22, EXP: 5/1/2014.

Recall Number: D-1024-2014

Reason for Recall
Labeling: Label Mixup: NIACIN TR, Capsule, 500 mg may have potentially been mislabeled as one of the following drugs: PERPHENAZINE, Tablet, 16 mg, NDC 00603506321, Pedigree: AD46265_49, EXP: 5/15/2014; MELATONIN, Tablet, 1 mg, NDC 47469000466, Pedigree: AD60240_14, EXP: 5/22/2014; CRANBERRY EXTRACT/VITAMIN C, Capsule, 450 mg/125 mg, NDC 31604014271, Pedigree: W002693, EXP: 6/5/2014; GLUCOSAMIN
Initiated
07-02-2013
Reported
01-29-2014
Quantity
504 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NIACIN TR, Capsule, 500 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00904063160.

Batch or Lot Expiration Information

Lot# NIACIN TR, Capsule, 500 mg has the following codes: Pedigree: AD46257_22, EXP: 5/15/2014; Pedigree: AD60240_17, EXP: 5/22/2014; Pedigree: W002696, EXP: 6/5/2014; Pedigree: AD73521_22, EXP: 5/30/2014; Pedigree: W003318, EXP: 6/18/2014.

Recall Number: D-855-2014

Reason for Recall
Labeling: Label Mixup: MEXILETINE HCL, Capsule, 150 mg may have potentially been mislabeled as the following drug: CALCIUM ACETATE, Capsule, 667 mg, NDC 00054008826, Pedigree: AD62865_4, EXP: 5/23/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
MEXILETINE HCL, Capsule, 150 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093873901.

Batch or Lot Expiration Information

Lot# MEXILETINE HCL, Capsule, 150 mg has the following codes: Pedigree: AD62865_7, EXP: 5/23/2014.

Recall Number: D-823-2014

Reason for Recall
Labeling: Label Mixup: CARBIDOPA/LEVODOPA, Tablet, 25 mg/250 mg may have potentially been mislabeled as the following drug: DIGOXIN, Tablet, 0.125 mg, NDC 00115981101, Pedigree: AD46426_22, EXP: 5/15/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
CARBIDOPA/LEVODOPA, Tablet, 25 mg/250 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093029401.

Batch or Lot Expiration Information

Lot# CARBIDOPA/LEVODOPA, Tablet, 25 mg/250 mg has the following codes: Pedigree: AD46426_28, EXP: 5/15/2014.

Recall Number: D-827-2014

Reason for Recall
Labeling: Label Mixup: NORTRIPTYLINE HCL, Capsule, 10 mg may have potentially been mislabeled as the following drug: VALSARTAN, Tablet, 80 mg, NDC 00078035834, Pedigree: AD70585_1, EXP: 5/29/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Capsules

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
NORTRIPTYLINE HCL, Capsule, 10 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093081001.

Batch or Lot Expiration Information

Lot# NORTRIPTYLINE HCL, Capsule, 10 mg has the following codes: Pedigree: AD70585_4, EXP: 5/29/2014.

Recall Number: D-946-2014

Reason for Recall
Labeling: Label Mixup: LACTOBACILLUS ACIDOPHILUS, Tablet, 35 MILLION may have potentially been mislabeled as the following drug: REPAGLINIDE, Tablet, 1 mg, NDC 00169008281, Pedigree: W003924, EXP: 6/28/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
100 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
LACTOBACILLUS ACIDOPHILUS, Tablet, 35 MILLION, Over The Counter, Distributed by: AidaPak Service, LLC, NDC 00536718101.

Batch or Lot Expiration Information

Lot# LACTOBACILLUS ACIDOPHILUS, Tablet, 35 MILLION has the following codes: Pedigree: W003865, EXP: 6/27/2014.

Recall Number: D-833-2014

Reason for Recall
Labeling: Label Mixup: SOTALOL HCL, Tablet, 80 mg may have potentially been mislabeled as one of the following drugs: DILTIAZEM HCL, Tablet, 120 mg, NDC 00093032101, Pedigree: AD30197_1, EXP: 5/9/2014; PROPRANOLOL HCL ER, Capsule, 60 mg, NDC 00228277811, Pedigree: AD54605_4, EXP: 5/20/2014.
Initiated
07-02-2013
Reported
01-29-2014
Quantity
202 Tablets

Recall Profile & Regulatory Data

Event ID About Event ID
Numerical designation assigned by FDA to a specific recall event.
65690
Classification About Classification
Relative degree of health hazard assigned by FDA.
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
Aidapak Services, LLC
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Product Type About Product Type
Broad category of product being recalled.
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Telephone
Distribution Pattern About Distribution Pattern
General area of initial distribution.
Repacked drugs were distributed in Arizona, California, Oregon, and Washington.
Termination Date About Termination Date
Date that FDA officially terminated the recall.
02-07-2014
Product Description About Product Description
Full technical description of the product.
SOTALOL HCL, Tablet, 80 mg, Rx only, Distributed by: AidaPak Service, LLC, NDC 00093106101.

Batch or Lot Expiration Information

Lot# SOTALOL HCL, Tablet, 80 mg has the following codes: Pedigree: AD30993_17, EXP: 5/9/2014; Pedigree: AD52778_85, EXP: 5/21/2014.